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Introduction 
For forty years, the United States government allowed economically 
disadvantaged1 African American men to be exploited in the name of 
research, although the research could not generate any benefit to so-
ciety.2 Specifically, from 1932 until 1972, government funded research-
ers enrolled economically disadvantaged African American men in the 
Tuskegee Syphilis Study to document the already known course of syp-
hilis, which led to the men suffering sores, fever, hair loss, weight loss, 
headaches, paralysis, blindness, dementia, and death.3 In exchange for 
free meals, medical exams, and burial insurance, the researchers pro-
mised the men that they would provide treatment for their “bad blood,” 
which could include “anemic blood to muscle aches, general malaise, 
disorders such as parasitic infections, gonorrhea, syphilis, and other ve-
nereal diseases.”4 Not only did the researchers lie about the purpose of 
the study, but also they intentionally deprived these men of “demon-
strably effective treatment in order not to interrupt the project, long 
 
1. Throughout the Article, I use economically disadvantaged to discuss children 
who lack access to essential goods such as food, housing, and health care. 
Although the term can be over inclusive, for clarity, I have used the word 
accepted in the medical research community. For more discussion, see Carol 
Levine, Changing Views of Justice after Belmont: AIDS and the Inclusion 
of “Vulnerable” Subjects, in The Ethics of Research Involving Human 
Subjects: Facing the 21st Century 105, 110 (Harold Y. Vanderpool ed., 
1996) (“Underlying the protectionist view of the selection of subjects is the 
assumption that research is risky . . . . If this is true, then subjects should be 
selected in a way that protects those whose social, demographic, or economic 
characteristics make them particularly vulnerable to coercion and exploi-
tation.”). 
2. Harriet A. Washington, Medical Apartheid: The Dark History of 
Medical Experimentation on Black Americans from Colonial 
Times to the Present 159–66 (2006) [hereinafter Washington]. See also 
Deleso Alford Washington, Examining the “Stick” of Accreditation for Medical 
Schools Through Reproductive Justice Lens: A Transformative Remedy for 
Teaching the Tuskegee Syphilis Study, 26 St. John’s J. C.R. & Econ. Dev. 
153, 158 (2011) [hereinafter Alford Washington] (noting that an earlier study 
had confirmed the existence of mass treatment options for syphilis); James 
H. Jones, Bad Blood: The Tuskegee Syphilis Experiment 2–4, 206–
08 (rev. ed., 1993) (describing the symptoms of syphilis and discussing the 
decision to withhold treatment from participants in the Tuskegee Syphilis 
Experiment). 
3. Jones, supra note 2, at 4. 
4. Washington, supra note 2, at 162. 
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after such treatment became generally available,” causing the unnecess-
ary disability and death of the men, their wives, and their children.5 
The study was not a therapeutic study because it was not testing a 
possible treatment of syphilis and blocked any access to treatment.6 
Additionally, the study was not a non-therapeutic study to attain gen-
eralizable knowledge because the medical community had already docu-
mented the disease process of syphilis.7 Thus, there was nothing gained 
from the study other than exploiting economically disadvantaged min-
orities.8  
The egregiousness of this study led to the creation and recognition 
of three Bioethical Principles: Respect for Persons (informed consent);9 
 
5. Belmont Report: Ethical Principles and Guidelines for the Protection of 
Human Subjects of Research, Report of the National Commission for the 
Protection of Human Subjects of Biomedical and Behavioral Research, 44 
Fed. Reg. 23,192, 23,194 (Apr. 18, 1979) [hereinafter Belmont Report]; 
Washington, supra note 2, at 159–60, 163. See also Alford Washington, 
supra note 2, at 177 (“By applying a reproductive justice lens to a reexami-
nation of the Tuskegee Syphilis Study, one ascertains that the government 
denied the women directly impacted by the study the right to not bear a 
child with congenital syphilis, because of the government doctors’ intention 
to study the effect of untreated syphilis on men (the husbands and intimate 
partners of the women who contracted syphilis) and, unbeknownst to them, 
passed the disease on to their unborn children.”). 
6.  See infra note 19 (distinguishing therapeutic from non-therapeutic research 
studies).  
7.  See supra note 2.  
8. Fred Gray, whose life and work we celebrate with this symposium, filed a 
lawsuit on behalf of the men who participated in the Study. Fred D. Gray, 
The Tuskegee Syphilis Study: The Real Story and Beyond 84 
(1998). After the lawsuit was filed on July 24, 1973, the government settled 
the case for approximately ten million dollars ($37,500 to research participants 
with syphilis who were alive as of July 23, 1973, $15,000 to the heirs of 
research participants with syphilis, $16,000 to research participants without 
syphilis who were alive as of July 24, 1973; and $5,000 to the heirs of research 
participants without syphilis). Id. at 98; Jones, supra note 2, at 216–17. 
Researchers directly involved in the study never apologized. Id. at 219. 
9. See 45 C.F.R. § 46.408 (2015) (providing “[r]equirements for permission by 
parents or guardians and for assent by children”). For a detailed discussion 
regarding the balance between the need for medical research studies in children 
and the need for informed consent, see Additional Protections for Children 
Involved as Subjects in Research, 48 Fed. Reg. 9814 (Mar. 8, 1983) (“[HHS] 
is prescribing additional requirements for protection of children involved as 
subjects in research”); Protection of Human Subjects, 43 Fed. Reg. 31,786 
(July 21, 1978) (“Adequate provisions must be made to obtain the assent of 
the child and the consent or permission of the parents or guardians whenever 
these are necessary.”); Nat’l Insts. of Health, U.S Dep’t of Health & 
Human Servs., NIH Policy and Guidelines on the Inclusion of 
Children as Participants in Research Involving Human Subjects 
(Mar. 6, 1998), http://grants.nih.gov/grants/guide/notice-files/not98-024. 
html [https://perma.cc/F993-Z6AS] [hereinafter NIH Guide] (setting forth 
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Beneficence (the best interest of the individual participating in the re-
search based on a benefit-risk analysis);10 and Justice (who participates 
in medical research and what benefit has to be given to groups who 
participate in medical research),11 which govern all medical research 
studies conducted by or funded by the federal government, except for 
specified circumstances, like emergency settings.12 Although these 
Bioethical Principles have the force of law,13 medical research studies 
conducted by or funded by the federal government continue to exploit 
 
“the policy and guidelines on the inclusion of children in research involving human 
subjects that is supported or conducted by the National Institutes of Health 
(NIH)”); Nat’l Comm’n for the Prot. of Human Subjects of Bio-
medical & Behavioral Research, U.S. Dep’t of Health, Educ. & 
Welfare, Publ’n No. (OS) 77-0004, Report and Recommendations: 
Research Involving Children 43–47 (1977) [hereinafter Commission 
Report] (discussing informed consent in the context of “research involving 
children”). Paul Ramsey and Richard McCormick provided the most influ-
ential discussion regarding autonomy and the use of children in medical re-
search studies. Paul Ramsey argued that there was a need for assent from 
children participating in medical research studies, and that “no parent is 
morally competent to consent that his child shall be submitted to hazardous 
or other experiments having no diagnostic or therapeutic significance for the 
child himself.” Paul Ramsey, The Patient as Person: Explorations 
in Medical Ethics 13 (1970). Conversely, Richard McCormick argued that 
children should participate in medical research studies with parental consent 
if it would benefit the child, even if only morally, and is a reasonable pre-
sumption of the child’s wishes. Richard A. McCormick, Experimentation in 
Children: Sharing in Sociality, 6 Hastings Ctr. Rep. 41, 41–42, 44 (1976). 
10. See 45 C.F.R. §§ 46.404–.407 (2016) (requiring an analysis of the risks and 
benefits to children as research subjects as a condition to receiving HHS fun-
ding or participation); NIH Guide, supra note 9 (summarizing “additional 
requirements under the HHS Regulations 45 CFR 46, Subpart D”); Co-
mmission Report, supra note 9, at 42–43 (assessing the “[r]isks and benefits 
of research involving children”). See also Loretta M. Kopelman, Children as 
Research Subjects: Moral Disputes, Regulatory Guidance, and Recent Court 
Decisions, 73 Mount Sinai J. Med. 596, 597 (2006) (arguing that as the 
courts have “reinforced the fact that the ‘best interest’ standard must be 
used for incompetent persons . . . . the failure to clarify the meaning of the 
pediatric regulations has sometimes misled generally risk-adverse institutions 
and dedicated investigators about what is permissible”); Michelle Oberman 
& Joel Frader, Dying Children and Medical Research: Access to Clinical 
Trials as Benefit and Burden, 29 Am. J.L. & Med. 301 (2003) (analyzing 
the intricacies of determining the “best interests” of the child in medical 
research). 
11. See 45 C.F.R. § 46.111(a)(3) (2015) (stating that the “IRB should take into 
account the purposes of the research and the setting in which the research 
will be conducted”). This section also prohibits the targeting of children for 
use in medical research studies. Id. § 46.111(b).  
12. 21 C.F.R. §§ 50.23–.24 (2012). 
13. 45 C.F.R. § 46.101 (2015). 
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economically disadvantaged minorities by using them for participation 
in medical research studies for which there is no benefit. 
Much of the work discussing the history and legacy of the Tuskegee 
Syphilis Study has focused on the violations of the Respect for Persons 
and Beneficence Principles.14 The discussion has rarely focused on the 
Justice Principle that prohibits exploitation.15 Exploitation is defined 
as the use of populations for research from which they will not benefit.16 
My Article begins to fill this void by critically analyzing the current 
limitations of the Justice Principle to address structural and institu-
tional racial biases in health care, which allow economically disadvan-
taged minorities to be exploited in medical research studies as they were 
in the Tuskegee Syphilis Study. Using research conducted on economi-
cally disadvantaged minority children as an example, my Article shows 
how even after the creation of the Justice Principle and the passage of 
the civil rights laws, structural and institutional racial biases remain 
and have led to the continued exploitation of economically disadvan-
taged minorities in medical research studies. 
Part I of the Article provides a descriptive overview of the purpose 
and structure of medical research studies and examines the parameters 
 
14. See Jones, supra note 2, at 216–17 (discussing harm endured by participants 
in the Tuskegee Syphilis Study who participated without informed consent). 
See generally Alford Washington, supra note 2 (addressing a “traditionally 
overlooked, historically marginalized and devalued aspect of our society: 
women in general and in particular, Black women, specifically in relation to 
healthcare, research and medical education”); Tuskegee’s Truths: Re-
thinking the Tuskegee Syphilis Study (Susan M. Reverby, ed., Univ. 
of N.C. Press, 2000) [hereinafter Tuskegee’s Truths] (discussing how men 
participated in the Tuskegee Syphilis Study “under the guise of treatment”); 
Susan M. Reverby, Examining Tuskegee: The Infamous Syphilis 
Study and Its Legacy (2009). 
15. Belmont Report, supra note 5, at 23,194. The Justice Principle also prohibits 
targeting. Targeting is the systematic selection of research subjects who are 
from vulnerable populations, such as racial minorities, children, and the eco-
nomically disadvantaged, “because of their easy availability, their compro-
mised position, or their manipulability, rather than for reasons directly related 
to the problem being studied.” Id. For a more detailed discussion concerning 
targeting, see Ruqaiijah Yearby, Missing the “Target”: Preventing the Unjust 
Inclusion of Vulnerable Children for Medical Research Studies, 42 Am. J.L. 
& Med. (forthcoming 2017) (discussing continued targeting in medical 
research involving children and proposing recommendations to prevent further 
targeting).  
16. See Belmont Report, supra note 5, at 23,194 (“[T]he selection of research 
subjects needs to be scrutinized in order to determine whether some classes 
(e.g., welfare patients, particular racial and ethnic minorities, or persons 
confined to institutions) are being systematically selected simply because of 
their easy availability, their compromised position, or their manipulability, 
rather than for reasons directly related to the problem being studied.”). 
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of the Justice Principle. Part II discusses the structural and institu-
tional biases that prevent economically disadvantaged minority child-
ren from accessing health care and how this leads to their exploitation 
in medical research studies. Structural racial bias measures how non-
race based factors, such as the delivery of health care based on ability 
to pay, indirectly affects economically disadvantaged minority child-
ren’s access to health care, whereas institutional racial bias focuses on 
the direct effects of institutional actions on economically disadvantaged 
minority children’s access to health care. In Part III, I propose several 
ways to put an end to exploitation, a violation of the Justice Principle 
in medical research studies. 
Specifically, I suggest that the Justice Principle be redefined to 
include the Human Development Approach that requires researchers to 
provide a benefit to the population from which the research subjects 
originated that alleviates some of the populations’ underlying problems, 
such as lack of access to health care. This type of benefit is required 
because oftentimes either the researcher’s institution or the researcher’s 
actions have caused some of the underlying problems, such as lack of 
access to health care.17 To measure whether the research fulfills the 
Human Development Approach and provides a benefit that alleviates 
some of the underlying problems, researchers should be required to use 
the Vulnerability and Equity Impact Assessment (VEIA) tool, which I 
have created based on the Health Equity Impact Assessment tool.18 
Using the VEIA, a newly created Board of Children would be 
responsible for approving all medical research studies seeking U.S. 
government funding that plan to use children. The Board would use 
the VEIA to determine if the research would exploit economically 
disadvantaged minority children in violation of the redefined Justice 
Principle. 
Redefining the Justice Principle to include the Human Development 
Approach, implementing the VEIA, and creating a Board to review all 
 
17. See Alex John London, Justice and the Human Development Approach to 
International Research, Hastings Ctr. Rep. 24, 32 (2005) (“[T]he minimalist 
approach does little to bring attention to the root causes of the developing 
world populations’ most pressing health needs. As a result, it perpetuates an 
ad hoc and piecemeal approach to the health needs of populations that already 
bear the greatest burden of disease and deprivation.”). 
18. See Rebecca Haber, Wellesley Inst., Health Equity Impact Asse-
ssment: A Primer (2010), http://www.wellesleyinstitute.com/wp-content/ 
uploads/2011/02/Health_Equity_Impact_Assessment_Haber.pdf [https:// 
perma.cc/Z3YT-HLL9] (“HEIA is a tool used to analyze a new program or 
policy's potential impact on health disparities and/or on health disadvantaged 
populations. It is an adaptation of health impact assessment (HIA) with an 
explicit focus on equity.”). See also Rainer Fehr, Environmental Health 
Impact Assessment., Evaluation of a Ten-Step Model, 10 Epidemiology Res. 
Inc. 618, 618 (1999) (identifying “key elements of an integrated environmental 
health impact assessment model”). 
Case Western Reserve Law Review·Volume 67·Issue 4·2017 
Exploitation in Medial Research 
1177 
medical research studies using children will prevent economically dis-
advantaged minority children from being exploited in medical research 
studies for the benefit of an unworthy society. 
I. Medical Research Studies Involving Children:  
The Structure and History 
There are two types of medical research studies involving human 
subjects: non-therapeutic and therapeutic.19 Regardless of the type of 
medical research study, all studies using children entail risk of psy-
chological and physical harm, as well as the possibility of stigma. In 
fact, countless children have suffered harm as a result of participating 
in medical research studies, often without any benefit to children.20 
However, economically disadvantaged minority children have been and 
continue to be overrepresented in medical research studies that do not 
provide a benefit to economically disadvantaged minority children.21 
This violates the Justice Principle. 
The Justice Principle was created by incorporating social justice 
into scientific endeavors to protect populations from being exploited. In 
 
19.  Therapeutic or beneficial research “means that if the hypothesis of the research 
is correct, the subjects who participate should receive direct benefit from 
their participation.” Leonard H. Glantz, Research with Children, 24 Am. 
J.L. & Med. 213, 231 (1998). Non-therapeutic research, on the other hand, 
involves “no prospect of direct benefit to individual subjects, but [is] likely 
to yield generalizable knowledge about the subject's disorder or condition.” Id.  
20. Id. at 215–17 (discussing various historical experiments subjecting children 
to risk and harm); see also Susan Lederer & Michael Grodin, Historical 
Overview: Pediatric Experimentation, in Children as Research Subjects: 
Science, Ethics, and Law 3–20 (1994) (surveying the history of the use 
of children as medical research subjects). Children have been exploited in 
medical research studies for conditions that were not limited to children. Id. 
Moreover, many medical research studies conducted on children have no 
scientific value and are stigmatizing. See Solomon R. Benatar, Global Health 
and Justice: Re-Examining Our Values, 27 Bioethics 297, 301–02 (2013) 
(discussing how grant money could be distributed more effectively to reduce 
child mortality); Iain Chalmers & Paul Glasziu, Avoidable Waste in the Pro-
duction and Reporting of Research Evidence, 374 Lancet 86, 86–89 (2009) 
(discussing wasteful and unnecessary research practices of the modern 
research landscape); Washington, supra note 2, at 271–96 (discussing scien-
tific research that has targeted and stigmatized Black children); Lainie 
Friedman Ross, Children in Medical Research: Access Versus 
Protection 48, 50 (2006) (discussing the overrepresentation of Black child-
ren in various categories of research, including potentially stigmatizing re-
search). 
21. Washington, supra note 2, at 271–96; Ross, supra note 20, at 48, 50; 
Vernellia R. Randall, Slavery, Segregation and Racism: Trusting the Health 
Care System Ain’t Always Easy! An African American Perspective on Bio-
ethics, 15 St. Louis U. Pub. L. Rev. 191, 199 (1996). 
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1979, the first discussion of the Justice Principle in medical research 
studies appeared in the United States Belmont Report.22 This report—
mandated by the United States Congress—not only defined the Justice 
Principle, but also provided the framework for which to apply the prin-
ciple to medical research studies.23 Since the codification of the Belmont 
Report in 1986,24 the Justice Principle has been applied to all medical 
research studies conducted by or funded by the federal government, 
except in emergency settings, as a means to protect vulnerable popu-
lations, such as economically disadvantaged minority children from be-
ing exploited.25 
A. Structure of Medical Research Studies Involving Human Subjects 
A non-therapeutic medical research study is conducted to obtain 
generalizable scientific knowledge.26 This research is done to learn more 
“about the subjects’ disorder or condition, which is of vital importance 
for the understanding or amelioration of the subjects’ disorder or condi-
tion.”27 An example of non-therapeutic research is the Kennedy Krieger 
lead study.28 
In the 1990s, Kennedy Krieger Institute researchers investigating 
cheap lead abatement techniques partnered with landlords to partially 
abate lead tainted housing in Baltimore, Maryland.29 In order to test 
the efficacy of the abatement procedures, the researchers—in collabor-
ation with the landlords—ensured that only families with healthy child-
ren lived in the lead tainted housing by agreeing to pay for lead abate-
 
22. Belmont Report, supra note 5, at 23,194. In fact, the Justice Principle was 
found only in the Belmont Report until 2000, when the World Medical Asso-
ciation added the principle to the Declaration of Helsinki, a renowned docu-
ment of bioethics for medical research. World Med. Ass’n, Declaration 
of Helsinki—Ethical Principles for Medical Research Involving 
Human Subjects (amended 2013), http://www.wma.net/en/30publications 
/10policies/b3/ [https://perma.cc/K73Y-9KTF]. For a discussion regarding 
the ethical documents that discuss the use of children in research trials, see 
Duane Alexander, Regulation of Research with Children: The Evolution from 
Exclusion to Inclusion, 6 J. Health Care L. & Pol’y 1 (2002).  
23. Belmont Report, supra note 5, at 23,192.  
24. See Ross, supra note 20, at 23 n.101. 
25. 45 C.F.R. § 46.101, 46.111 (2015) (identifying the scope of the policy’s 
application and summarizing criteria for compliance). 
26. Id. § 46.406(c). 
27. Id.  
28. See Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807, 811–17 (Md. 2001) 
(describing the Kennedy Krieger study in detail). 
29. Id. at 811–12.  
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ment procedures if the landlords rented to families with young child-
ren.30 Although the information given to parents “implied that the 
study was protecting their children from lead damage and promised to 
inform parents of any hazards,”31 the study was non-therapeutic32 
because it was conducted to find out more “about the subjects’ disorder 
or condition which is of vital importance for the understanding or ame-
lioration of the subjects’ disorder or condition . . . .”33 
A therapeutic medical research study tests a vaccine, drug, or 
medical device for the treatment of a disease.34 An example of a thera-
peutic medical research study is the testing of HIV/AIDS drugs. There 
are five phases of therapeutic medical research studies: Phase 0, I, II, 
III, and IV.35 Using drug medical research studies as an example, each 
phase is discussed below. 
In a Phase 0 drug study, research is conducted using at most ten 
people and involves the administration of small doses of an experi-
mental drug over a short period of time to determine if there is any 
pharmacological effect.36 The purpose of the study is to evaluate whe-
ther there is any effect in humans before undertaking Phase I and II 
drug studies.37 Unlike Phase I drug studies, there is no therapeutic 
 
30.  Id. at 812.  
31. Washington, supra note 2, at 292. 
32. Grimes, 782 A.2d at 811–12. There were many problems with the study. In 
fact, the researchers did not notify the parents of their children’s elevated 
lead levels or lead hot spots in the house. Id. at 825–31. As a result, many of 
the healthy children suffered exposure to lead. Id. Exposure to lead can cause 
inattention, irritability, hyperactivity, learning and reading delays, delayed 
growth and hearing loss, permanent brain damage, and even death. Lead 
Exposure in Children Affects Brain and Behavior, Am. Acad. of Child & 
Adolescent Psychiatry (Nov. 2012), http://www.aacap.org/aacap/ 
fffprint/article_print.aspx?dn=Lead-Exposure-In-Children-Affects-Brain-
And-Behavior-045 [https://perma.cc/L4AP-YNTN?type=image] [hereinafter 
Lead Exposure in Children]. 
33. 45 C.F.R. § 46.406(c) (2015). 
34. See, e.g., id. § 46.405 (“HHS will conduct or fund research in which the IRB 
finds that more than minimal risk to children is presented by an intervention 
or procedure that holds out the prospect of direct benefit for the individual 
subject, or by a monitoring procedure that is likely to contribute to the sub-
ject’s well-being . . . .”). 
35. U.S. Nat’l Insts. of Health, Glossary of Common Site Terms, Clinical 
Trials.gov, http://clinicaltrials.gov/ct2/info/glossary#Phasel [https:// 
perma.cc/T2FJ-JAF3] (last visited Feb. 20, 2017) [hereinafter Clinical Trial 
Glossary]. 
36. See id. (explaining that Phase 0 “involv[es] very limited human exposure to 
the drug, with no therapeutic or diagnostic goals”). 
37. What are the Phases of Clinical Trials?, Am. Cancer Soc’y, https:// 
www.cancer.org/treatment/treatments-and-side-effects/clinical-trials/what-
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intent and little to no toxic effect in a Phase 0 drug study, which is 
primarily done for cancer drugs and therapies.38 
In a Phase I drug study, research is conducted using a small number 
of subjects, less than 100 people, to obtain information regarding the 
safety and efficacy of the candidate drug on human subjects.39 Research 
that obtains information from several hundred subjects regarding the 
subjects’ immune system’s response, the efficacy of the drug on different 
populations, and the effect of different doses on the population is con-
ducted in a Phase II drug study.40 
After preliminary evidence has been obtained suggesting the effect-
iveness of a drug, a Phase III drug study is conducted “to gather addi-
tional information to evaluate the overall benefit-risk relationship of the 
drug and provide an adequate basis for physician labeling.”41 Research-
ers determine the efficacy of the drug for treating the disease by follow-
ing anywhere from 300 to 3,000 subjects.42 This is the last Phase before 
the drug is marketed and distributed. Phase IV is the final step in drug 
studies. It includes “postmarket requirement and commitment studies 
. . . . [to] gather additional information about a drug’s safety, efficacy, 
or optimal use.”43 The main difference between each phase is the 
purpose of the study and the benefit. In Phase 0, I, and II studies, the 
 
you-need-to-know/phases-of-clinical-trials.html [https://perma.cc/BN2G-
RJ3L] (last updated Feb. 7, 2017).  
38.  Id.; Clinical Trial Glossary, supra note 35.  
39. Step 3: Clinical Research, U.S. Food & Drug Admin., https://www 
.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm#Clinical_Research
_Phase_Studies [https://perma.cc/EW79-X2AP] (last updated Oct. 14, 
2016) [hereinafter FDA Clinical Research]; Clinical Trial Glossary, supra 
note 35. 
40. FDA Clinical Research, supra note 39. 
41. Ruth Frost, Trial Phase Values—Include v4.4, Nat’l Cancer Inst., 
https://wiki.nci.nih.gov/display/CTRPdoc/Trial+Phase+Values+-+Include 
+v4.4 [https://perma.cc/S8Y4-QGX9] (last updated Dec. 07, 2016).  
42. FDA Clinical Research, supra note 39. 
43. Clinical Trial Glossary, supra note 35. See also Leslie Pickering Francis, 
Legitimate Expectations, Unreasonable Beliefs, and Legally Mandated Cov-
erage of Experimental Therapy, 1 Ind. Health L. Rev. 213, 228 (2004) 
(“Phase IV trials undertake continued collection of data after a new drug is 
given marketing approval based on data from earlier trials. The goal of Phase 
IV is to collect data on an ongoing basis as an approved therapy becomes 
employed in the general population of patients in need of treatment. Distri-
bution of a therapy into the general population of patients, outside the research 
context, may reveal quite different aspects of the therapy’s risks and bene-
fits.”). 
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goal is primarily the attainment of scientific knowledge, whereas in 
Phase III and IV studies, the goal is treatment.44 
Overall, regardless of the type of research being conducted, ther-
apeutic or non-therapeutic, medical research studies offer the prospect 
of benefit to society. However, the Justice Principle requires that the 
population from which those serving as research subjects originate re-
ceive a benefit. Thus, if economically disadvantaged minority children 
serve as research subjects for medical research studies, whether thera-
peutic or non-therapeutic, all economically disadvantaged minority 
children should benefit from the studies either by receiving access to 
the drug or having the knowledge ascertained from the research used 
to assist them. 
B. The Belmont Report 
In the early 1970s, the U.S. Senate Committee on Labor and Hu-
man Resources held hearings on some of America’s most egregious 
medical research studies, such as the Willowbrook study45 and the 
 
44. See Francis, supra note 43, at 227–28 (describing the purpose and scientific 
value underlying each phase). 
45. For fifteen years (1956–1971) researchers conducted non-therapeutic medical 
research studies on children at the Willowbrook State School—an institutional 
facility for “mentally defective persons” on Staten Island, New York—to 
obtain scientific knowledge of “the natural history of hepatitis and the effects 
of gamma globulin in preventing or moderating its effects.” Carl H. Cole-
man et al., The Ethics and Regulation of Research with Human 
Subjects 39 (2005). Researchers infected healthy children—thus, the study 
was not to treat a disease from which the children suffered. Early in the 
study, the children were fed “extracts of stools from infected children, while 
later subjects received injections of more purified virus preparations.” Id. 
The children were then gauged to determine the effects of gamma globulin 
in combating it. A hepatitis vaccine was developed due to this study. Id. As 
a result of the study, healthy children were infected with a life-long debili-
tating disease so that researchers could develop a vaccine, which the infected 
children could never use, and as a result of the studies, the children were 
subjected to costly treatment for the rest of their lives. The researchers de-
fended their research because there were outbreaks of hepatitis at the school, 
so they assumed that the children would eventually acquire the disease. Id. 
At the time of the study, several major medical journals (the Journal of the 
American Medical Association and the New England Journal of Medicine) 
published the results of the study, commending the researchers for their use 
of vulnerable children and asserting that the children actually benefited “from 
being infected under carefully controlled research conditions and receiving ex-
pert attention.” Id. However, some researchers and scholars disagreed, allud-
ing to the fact that healthy children were fed stool extracts and received no 
benefit from the study because there is no cure for hepatitis. Furthermore, 
many argued that the choice to use that population seems to have been driven 
by the convenience of the children, not any lofting moral intentions. See id. at 
40 (describing coercive tactics used by institutional directors to secure the 
consent by parents for their childrens’ participation in the study). 
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Tuskegee Syphilis study.46 As a result of the hearings, Congress created 
the National Commission for the Protection of Human Subjects of Bio-
medical and Behavioral Research (Commission)47 and imposed a mora-
torium on research conducted or supported by the U.S. Department of 
Health and Human Services (HHS)48 until adequate protections for 
research subjects were developed.49 
The Belmont Report was an outgrowth of the Commission’s deli-
berations regarding ethical protections and a 1976 conference at the 
Smithsonian Institution’s Belmont Conference Center.50 In the Belmont 
Report, the Commission selected Justice as one of the three fundamen-
tal ethical principles to address the exploitation of vulnerable groups 
for medical research studies.51 The Commission noted that in the United 
States the burden of participating in medical research studies was borne 
principally by the economically disadvantaged while the rich enjoyed 
 
46. The Tuskegee Syphilis Study, conducted from 1932 through 1972, denied 
standard access to treatment to economically disadvantaged African-American 
men. See Belmont Report, supra note 5, at 23,194 (describing the recruitment 
of “disadvantaged, rural black men” to the Tuskegee study); Jones, supra 
note 2, at 206–19 (discussing the evolution of the Tuskegee Study). 
47. The Commission was composed of eleven members appointed by the Secretary 
of HHS. National Research Act of 1974, Pub. L. No. 93-348, § 201(a), 88 
Stat. 342, 348 (codified as amended in scattered sections of 42 U.S.C). The 
National Research Act advised the Secretary of HHS to choose the members 
of the Commission from “individuals distinguished in the fields of medicine, 
law, ethics, theology, philosophy, humanities, the biological, physical, behav-
ioral, and social sciences, health administration, government, and public 
affairs.” Id. § 201(b)(1). Five of the members of the Commission had to be 
individuals “engaged in biomedical or behavioral research involving human 
subjects.” Id. Members of the Commission included: Dorothy I. Height, Presi-
dent, National Council of Negro Women, Inc., Albert R. Jonsen, Ph.D., Asso-
ciate Professor of Bioethics, University of California at San Francisco, and 
Patricia King, J.D., Associate Professor of Law, Georgetown University Law 
Center, and others. Belmont Report, supra note 5, at 23,192. 
48. Prior to 1980, the U.S. Department of Health and Human Services (HHS) 
was called the U.S. Department of Health, Education, and Welfare. Depart-
ment of Education Organization Act, Pub. L. No. 96-88 § 509(a), 93 Stat. 
668, 695 (1979) (codified at 20 U.S.C. § 3508 (2006)). However, to avoid 
confusion when discussing events before and after the name change, I refer 
to the agency only as HHS. 
49. National Research Act § 472(b)(1), 88 Stat. at 343 (codified as amended at 
42 U.S.C. § 289l-1). The National Research Act of 1974 also required HHS 
to develop and publish policies for the protection of human subjects in the 
Code of Federal Regulations. Id. § 205, 88 Stat. at 351. 
50. Belmont Report, supra note 5, at 23,192. 
51. Id. at 23,194. The two other principles were Respect for Persons and Bene-
ficence. Id. 
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the benefits, as evidenced by the Tuskegee Syphilis Study.52 To address 
this inequitable burdening of the poor and minorities, the Report in-
cluded the Justice Principle based on John’s Rawls Egalitarian theory 
as refined by Tom Beauchamp and James Childress. 
According to John Rawls, the Justice Principle encompasses fair-
ness and equity, which “are not subject to political bargaining or to the 
calculus of social interests.”53 Unlike Utilitarianism that allows for harm 
for the benefit of the greater good, Rawls’ notes that “justice denies 
that the loss of freedom for some is made right by a greater good shared 
by others. It does not allow that the sacrifices imposed on a few are 
outweighed by the larger sum of advantages enjoyed by many.”54 Add-
ing to John Rawls’ theory, Tom Beauchamp and James Childress sub-
mit that Egalitarianism imposes a “positive societal obligation to reduce 
or eliminate barriers that prevent fair equality of opportunity, an oblig-
ation that extends to programs to correct or compensate for various 
disadvantages.”55 Based on this refined Egalitarian theory of Justice, 
the Commission used the Justice Principle to answer the questions: 
“Who ought to receive the benefits of research and bear its burdens?”56 
Specifically, the Commission defined what is just and unjust in the use 
of research subjects. 
In selecting research subjects, the Justice Principle requires that 
researchers ensure that disadvantaged groups such as minorities, wo-
men, children, the institutionalized mentally infirm, prisoners, and the 
economically disadvantaged57 are not “being systematically selected 
simply because of their easy availability, their compromised position, 
or their manipulability, rather than for reasons directly related to the 
problem being studied.”58 The Commission reasoned that: 
[W]henever research supported by public funds leads to the de-
velopment of therapeutic devices and procedures, justice demands 
both that these not provide advantages only to those who can 
afford them and that such research should not unduly involve 
 
52. Id.  
53. John Rawls, A Theory of Justice 3–4 (Harvard Univ. Press rev. ed., 
1999). Widely considered as the most significant contribution to law and 
philosophy, John Rawls created Egalitarianism as an alternative concept to 
the Utilitarian theory of justice. See id. at xvii–xviii (presenting an “alternative 
systematic account of justice”). 
54. Id. at 3. 
55. Tom Beauchamp & James Childress, Principles of Biomedical 
Ethics 248 (6th ed. 2009). 
56. Belmont Report, supra note 5, at 23,194. 
57. Id. at 23,194, 23,196–97. 
58. Id. at 23,194. 
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persons from groups unlikely to be among the beneficiaries of sub-
sequent applications of the research.59 
According to the Commission, an injustice occurs during medical 
research when a benefit is denied to a person without good reason or a 
burden is unduly imposed on a person, whereas Justice requires “that 
equals ought to be treated equally.”60 As applied to medical research, 
“the principle of justice gives rise to moral requirements that there be 
fair procedures and outcomes in the selection of research subjects” on 
two levels: individual and social.61 On the individual level, researchers 
should include the disadvantaged in potentially beneficial research that 
is usually reserved for the rich,62 instead of using them for non-thera-
peutic and dangerous medical research studies. On the social level, re-
searchers must draw a distinction “between classes of subjects that 
ought, and ought not, to participate in any particular kind of research, 
based on the ability of members of that class to bear burdens and on 
the appropriateness of placing further burdens on already burdened per-
sons.”63 The Belmont Report noted that it was not fair for the eco-
nomically disadvantaged, who rely on public funds for health care, to 
be considered as preferred research subjects for publicly funded research 
because of their need to access health care.64 Thus, there is an order of 
preference in the selection of research subjects, such that researchers 
should use the rich before the economically disadvantaged, the majority 
before minorities, and adults before children. Moreover, there is a re-
quirement that if a population serves as research subjects for the stu-
dies, that population should receive a benefit from the research.65 
On an individual level, the Justice Principle requires inclusion of 
vulnerable groups for potentially beneficial research,66 while on a social 
 
59. Id. (emphasis added). 
60. Id. 
61. Id. at 23,196. 
62. Id. 
63. Id. 
64. Id. at 23,197. 
65. The requirement of a benefit to the individuals who serve as research subjects 
is addressed by the Beneficence Principle. 45 C.F.R. §§46.404–.407 (2010); 
NIH Guide, supra note 9; Commission Report, supra note 9, at 5–10; see 
also Kopelman, supra note 10, at 597 (discussing how the United States 
balances potential harms and benefits in approving studies); Oberman & 
Frader, supra note 10, at 301 (discussing how the perceived vulnerability of 
children to medical experimentation led to federal regulation). It is also 
discussed in the prohibition against targeting under the Justice Principle. 
See Yearby, supra note 15 (discussing how the Justice Principle prohibits 
targeting subjects from vulnerable populations). 
66. Belmont Report, supra note 5, at 23,196. 
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level this inclusion must be balanced to protect vulnerable groups from 
being overburdened.67 Nevertheless, even after researchers balance the 
individual and social level requirements of the Justice Principle, the use 
of certain classes of people for research may be unjust because of “social, 
racial, sexual and cultural biases institutionalized in society” that place 
a class of people in a vulnerable and compromised position, easily mani-
pulated into participation in medical research studies, without any ben-
efit to the population from which the subject originated.68 
For example, over three decades of empirical research studies show 
that racial bias institutionalized in society prevents many African Am-
ericans from receiving a quality education, obtaining jobs, and accessing 
housing in safe, diverse, and environmentally-friendly neighborhoods.69 
 
67. Id. 
68. Id. 
69. See, e.g., Martha E. Lang & Chloe E. Bird, Understanding and Addressing 
the Common Roots of Racial Health Disparities: The Case of Cardiovascular 
Disease & HIV/AIDS in African Americans, 25 Health Matrix 109, 121–
24 (2015) (discussing how negative health results from the somatic effects of 
racism and an allostatic load, how CVD rates have declined slower in African 
American populations than white populations, and how the mortality rate 
for African Americans from CVD is greater than in white populations); 
Ruqaiijah Yearby, Sick and Tired of Being Sick and Tired: Putting an End 
to Separate and Unequal Health Care in the United States 50 Years After 
the Civil Rights Act of 1964, 25 Health Matrix 1 (2015) (discussing racially 
separate and unequal health care in the United States); Richard Delgado, 
Two Ways to Think About Race: Reflections on the Id, the Ego, And Other 
Reformist Theories of Equal Protection, 89 Geo. L.J. 2279 (2001) 
(discussing the application of Critical Race Theory to economic issues); 
Andrew Grant-Thomas & John A. Powell, Toward a Structural Racism 
Framework, Poverty & Race, Nov.–Dec. 2006, at 3 (arguing for a 
structural racism framework as an approach to remedying inequality); Ian F. 
Haney López, The Social Construction of Race: Some Observations on 
Illusion, Fabrication, and Choice, 29 Harv. C.R.-C.L. L. Rev. 1, 6–7, 10–
17 (1994) (rejecting the idea of biological race and criticizing the continued 
reliance of conceptions of biological race in the law); Charles R. Lawrence 
III, The Id, the Ego, and Equal Protection: Reckoning with Unconscious 
Racism, 39 Stan. L. Rev. 317 (1987) (critiquing the doctrine of discrimi-
natory purpose and discussing unconscious racism); Kimberle Crenshaw, 
Demarginalizing the Intersection of Race and Sex: A Black Feminist Critique 
of Antidiscrimination Doctrine, Feminist Theory and Antiracist Policies, U. 
Chi. Legal F. 139, 139–40 (1989) (stating how Black women are margin-
alized in conversations about racism and sexism). These disadvantages affect 
the health of those that are disadvantaged. See Paula Braveman et al., 
Socioeconomic Disparities in Health in the United States: What the Patterns 
Tell Us, 100 Am. J. Pub. Health S186, S189 (Supp. 1 2010) (discussing the 
results of a study which found that relative advantage in society, rather than 
merely whether one is above or below a certain income level, is an indicator 
of health); Leith Mullings & Amy J. Schulz, Intersectionality and Health: An 
Introduction, in Gender, Race, Class and Health: Intersectional 
Approaches 3, 12 (Leith Mullings & Amy J. Schulz eds. 2006) (discussing 
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Studies show that African Americans seeking employment have a hard-
er time obtaining employment because non-African American managers 
tend to hire more Caucasians.70 Also, African Americans with non-Cau-
casian names receive fifty percent less callbacks than African Americans 
with Caucasian sounding names.71 As a result, many African Americans 
are more likely to be unemployed or employed with no health insurance. 
Lacking health insurance or money to pay for health care, African 
Americans are left in a compromised position and easily manipulated 
into participating in medical research studies to obtain access to health 
care. Consequently, even if researchers fairly select African Americans 
as research subjects, these institutional racial biases that prevent them 
from accessing health care make their use as research subjects a vio-
lation of the Justice Principle because they will not receive a benefit 
even if the research leads to a treatment, since they do not have access 
to health care.72 
Beginning in the 1980s, the Belmont Report in its entirety, was 
adopted by sixteen federal agencies and departments, including HHS, 
and codified in 45 C.F.R. Part 46 (the Common Rule).73 In fact, not 
only did the Common Rule make the Justice Principle law, but it also 
explicitly defined the groups protected by the Justice Principle as 
 
how different forms of racism affect health, such as structural racism, insti-
tutional racism, and interpersonal racism); Pamela Braboy Jackson & David 
R. Williams, The Intersection of Race, Gender, and SES: Health Paradoxes, 
in Gender, Race, Class and Health: Intersectional Approaches 
131 (Leith Mullings & Amy J. Schulz eds. 2006) (examining how race, 
gender, and socioeconomic status interact to impact health); Ruth E. Zam-
brana & Bonnie Thornton Dill, Disparities in Latina Health: An Intersectional 
Analysis, in Gender, Race, Class and Health: Intersectional 
Approaches 192 (Leith Mullings & Amy J. Schulz eds. 2006) (examining the 
effects of various factors on health disparities); Peter Franks et al., The Burden 
of Disease Associated with Being African-American in the United States and 
the Contribution of Socio-Economic Status, 62 Soc. Sci. & Med. 2469 (2006) 
(finding that socio-economic status differences in African-Americans, com-
pared to that of whites, contribute to a disparity in health-related quality of 
life). 
70. Michael Luo, In Job Hunt, College Degree Can’t Close Racial Gap, N.Y. 
Times (Nov. 30, 2009), http://www.nytimes.com/2009/12/01/us/01race 
.html?_r=0 [https://perma.cc/8P78-WZZ3].  
71. Marianne Bertrand & Sendhil Mullainathan, Are Emily and Greg More 
Employable Than Lakisha and Jamal? A Field Experiment on Labor Market 
Discrimination (Nat’l Bureau of Econ. Research, Working Paper No. 9873, 
2003). 
72. See Belmont Report, supra note 5, at 23,196. 
73. See Ross, supra note 20, at 23 n.101 (listing agencies). 
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vulnerable populations that shall not be exploited.74 Vulnerable popu-
lations include minorities, children, prisoners, pregnant women, men-
tally disabled persons, and economically or educationally disadvantaged 
persons.75 The Common Rule generally governs all research studies 
conducted by or funded by the federal government.76 
C. The Common Rule 
Institutions receiving federal funding to conduct medical research 
studies must enter into a contractual agreement with the federal gov-
ernment, called an assurance,77 asserting that they will comply with the 
Common Rule.78 Once an institution’s assurance is approved and it 
receives federal funding, the federal government requires that all re-
search conducted by the institution regardless of who funds it comply 
with 45 C.F.R. Part 46.79 The Office for Human Research Protections 
(OHRP), a federal agency housed within HHS, is responsible for en-
suring that institutions comply with their assurances.80 To fulfill this 
task, OHRP may request additional information in writing, conduct 
telephone interviews, or conduct site visits.81 These visits can be random 
or in response to allegations of noncompliance with the Common Rule.82 
 
74. 45 C.F.R. § 46.111 (2015).  
75. Id.; The Office for Human Research Protections (OHRP) Guidebook con-
cerning medical research studies adds minorities to the list of vulnerable 
populations. See U.S. Dep’t of Health & Human Servs., Office for 
Human Research Prots., Institutional Review Board Guidebook 
(1993), https://archive.hhs.gov/ohrp/irb/irb_chapter6ii.htm#g10 [https:// 
perma.cc/TZ97-R6U8]. 
76. Coleman et al., supra note 45, at 107. 
77. There are several types of assurances. See generally Lori A. Alvino, Who’s 
Watching the Watchdogs? Responding to the Erosion of Research Ethics by 
Enforcing Promises, 103 Colum. L. Rev. 893, 899–900 (2003) (discussing 
Single Project Assurances, Multiple Project Assurances, and Cooperative 
Project Assurances, and how those assurances must be replaced by Federal 
Wide Assurances when they expire). 
78. 45 C.F.R. § 46.103 (2015).  
79.  Id.  
80. Id.  
81.  Coleman et al., supra note 45, at 136–37; Memorandum from Director, 
OHRP, to OHRP Staff, Regarding Compliance Oversight Procedures (Dec. 
4, 2000), in The Ethics and Regulations of Research with Human 
Subjects 138, 141 (2005) [hereinafter OHRP Memorandum]. 
82. Coleman et al., supra note 45, at 136–37. For government funded medical 
research studies in which there has been an allegation of noncompliance, 
OHRP initiates an investigation. Id. at 140–41 (detailing the sequence of 
events in compliance investigations). 
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When reviewing allegations of noncompliance, OHRP grants the 
institution an opportunity to refute the allegations.83 Once additional 
information is obtained, OHRP determines whether the institution has 
violated the law.84 OHRP issues corrective action for instances of non-
compliance, which is in “the best interests of human research subjects, 
and to the extent possible, the institution, the research community, and 
HHS.”85 Corrective action may include restriction or withdrawal of app-
roval for an institution’s assurance and suspension or permanent remov-
al from participation in specific projects.86 Information regarding 
allegations and findings of noncompliance can be found on OHRP’s 
website.87 
OHRP is responsible for reviewing compliance at the institutional 
level.88 Every institution that has an assurance with OHRP is respon-
sible for ensuring that individual medical research studies conducted by 
 
83. OHRP Memorandum, supra note 81, at 139. 
84. Id. at 141. 
85. Id. 
86. Id. at 140. Many, including the former Secretary of HHS, have argued that 
OHRP has failed to issue meaningful sanctions. See L. Song Richardson, 
When Human Experimentation Is Criminal, 99 J. Crim. L. & Criminology 
89, 124–26 (2009) (discussing how institutions that are supposed to police 
research fail to deter unethical conduct because of their reliance on self-
policing); Donna Shalala, Protecting Research Subjects—What Must Be 
Done, 343 New Eng. J. Med. 808 (2000) (arguing for a strengthening of the 
regulatory system protecting human research subjects). One form of sanction 
the OHRP imposes is posting a letter of violation on its website. OHRP 
Memorandum, supra note 81, at 141. See generally OHRP Determination 
Letters, HHS.gov, http://www.hhs.gov/ohrp/compliance-and-reporting/ 
determination-letters/index.html [https://perma.cc/9C4X-KR8V] (exhibiting 
a searchable database of OHRP determination letters). However, in the past 
when the public pressure has become too much, some institutions have 
voluntarily stopped the research studies, while others have continued the 
research studies. See generally David B. Resnik, Research Ethics Timeline, 
Nat’l Insts. Of Health, http://www.niehs.nih.gov/research/resources/ 
bioethics/timeline/ [https://perma.cc/LX68-JKNP] (last updated Feb. 13, 
2017) (identifying 1972 as the year “the national media and Congress [began] 
focus[ing] on unethical research practices with human subjects, including the 
Tuskegee study”). Yet, this is an erratic outcome that simply depends on how 
much media attention the study received. See id. (providing a timeline that 
suggests unethical research studies have persisted despite greater national 
attention and media scrutiny). 
87. Office for Human Research Protections, https://www.hhs.gov/ohrp/ 
[https://perma.cc/R5ZV-EGNV] (last visited Feb. 19, 2017). 
88. Compliance and Reporting, Off. for Human Research Prots., https:// 
www.hhs.gov/ohrp/compliance-and-reporting/index.html [https://perma.cc/ 
TX6U-QPKS] (last visited Mar. 11, 2017). 
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those affiliated with the institution comply with the Common Rule.89 
To accomplish this task, all institutions and federal agencies that enter 
into an assurance with OHRP have an Institutional Review Board 
(IRB).90 There are an estimated 3,000 to 5,000 IRBs, which serve as the 
main protection for vulnerable populations in medical research 
studies.91 
Before researchers can be funded by the United States government 
or conduct medical research studies using human subjects in the United 
States, they must submit a research protocol to their IRB.92 A complete 
research protocol includes a statement of compliance with the ethical 
principles, including the Justice Principle.93 The IRB reviews all written 
research protocols in application for medical research studies using 
human subjects to ensure that the proposed studies are ethical.94 If the 
IRB finds that the research protocol is ethical, they can approve the 
research to be conducted and/or submitted for funding to the United 
States government.95 The IRB can also require modifications in the re-
search protocol or disapprove any research protocol.96 
In terms of the Justice Principle, the IRB is required to ensure that 
the “[r]isks to subjects are minimized: (i) [b]y using procedures which 
are consistent with sound research design and which do not unnecessar-
ily expose subjects to risk,”97 and the “[s]election of subjects is equi-
table.”98 This section prohibits the exploitation of vulnerable popu-
lations, which is the use of vulnerable populations for medical research 
studies that vulnerable populations will not benefit from, while the rest 
of society act as free riders reaping the benefits without sacrifice.99 If 
 
89.  45 C.F.R. § 46.101(a)(2) (2015). 
90. IRBs and Assurances, Off. for Human Research Prots., https://www 
.hhs.gov/ohrp/irbs-and-assurances.html [https://perma.cc/GNT3-8P3P] (last 
visited Mar. 11, 2017) 
91.  Alison Wichman, Institutional Review Boards, in Principles and Practice 
of Clinical Research 47, 56 (John I. Gallin & Frederick P. Ognibene 
eds., 2007). 
92. 45 C.F.R. § 46.101(a)(2) (2015). 
93. Id. § 46.103(b)(1). 
94.  Id.  
95.  Id. § 46.103(a). 
96. See 10 C.F.R. § 745.101 (2015) (defining the scope of IRB policy for research 
with human subjects); 28 C.F.R. § 46.101 (2015) (same); 28 C.F.R. § 46.109(a) 
(2015) (stating that an IRB can approve, disapprove, or require modification 
of research). 
97. 45 C.F.R. § 46.111(a)(1) (2015) (emphasis added). 
98. Id. § 46.111(a)(3) (emphasis added). 
99. Id. 
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the IRB fails to ensure that vulnerable populations are not exploited, 
then OHRP may issue a corrective action.100 
In 1990, there was a paradigm shift in the use of the Justice Prin-
ciple, which has allowed researchers to exploit economically disadvan-
taged minority children.101 Specifically, instead of using the Justice Pri-
nciple to protect economically disadvantaged minority children from 
exploitation, now researchers use the Justice Principle to include eco-
nomically disadvantaged minority children in medical research studies 
that not only unnecessarily exposing them to risks, causing harm, but 
also failed to provide a benefit to the population from which they ori-
ginated.102 
II. Inclusion, Exploitation, and Bias 
In the 1990s, Congress passed laws to ensure that a number of pop-
ulations (women, minorities, children, and the economically disadvan-
taged), who were perceived as being left out of medical research, were 
included in medical research studies.103 Participating in medical 
research studies provides economically disadvantaged minority 
children, who are research subjects, with access to health care during 
the study.104 However, because of structural and institutional racial 
biases that limit access to health care to those who can pay, 
economically disadvantaged minority children’s access to health care 
 
100.  OHRP Memorandum, supra note 81, at 139–40.  
101. See Michael I. Shevell, Ethics of Clinical Research in Children, 9 Seminars 
in Pediatric Neurology 46, 48 (2002) (discussing the effect of the 
adoption of guidelines in 1991). 
102. See generally id. at 51 (2002) (discussing the tensions in the Justice Principle 
between including vulnerable populations and excluding vulnerable pop-
ulations); Levine, supra note 1, at 116 (discussing how research involving sick 
children presents particularly difficult situations for investigators). 
103. In 1993, Congress enacted the NIH Revitalization Act to increase female and 
minority participation in medical research studies and in 1997, Congress 
passed the Food and Drug Administration Modernization Act to incentivize 
pharmaceutical companies to conduct medical research on children by pro-
viding an additional six months of patent exclusivity to the company even if 
the results from the medical research studies were negative or inconclusive. 
National Institutes of Health Revitalization Act of 1993, Pub. L. No. 103-43, 
§ 206, 107 Stat. 122, 148 (codified as amended at 42 U.S.C. § 282(h) (1994)); 
Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-
15, § 111, 111 Stat. 2296, 2305–09 (codified as amended at 21 U.S.C. § 355a 
(2000)); see also Ross, supra note 20, at 48–50 (providing data on the use 
of child subjects in research). 
104. See NIH Clinical Research Trials and You, Nat’l Insts. of Health, 
https://www.nih.gov/health-information/nih-clinical-research-trials-you/ 
basics#1 [https://perma.cc/F9E5-5JU5] (last visited Mar. 21, 2017) (dis-
cussing how a benefit to participating in research is medical care). 
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ends once the medical research study ends. As a result, economically 
disadvantaged minority children are being exploited in medical research 
studies, since the population from which they originate will not benefit 
from the research because they lack access to health care and the 
research unnecessarily exposes them to risk.105 Inclusion without a 
benefit is exploitation, which is a violation of the Justice Principle. 
A. Inclusion 
The Justice Principle was only in effect for a few years when the 
federal government shifted its definition from protection of vulnerable 
populations to inclusion of vulnerable populations to promote greater 
access to medical research studies.106 This shift in meaning was a result 
of the Human Immunodeficiency Virus and the Acquired Immune De-
ficiency Syndrome (HIV/AIDS) epidemic and the perceived lack of par-
ticipation of economically disadvantaged minority children in medical 
research studies.107 
As Carol Levine notes, medical research studies became synony-
mous with treatment during the HIV/AIDS epidemic.108 Due to the 
HIV/AIDS crisis, people were dying with no hope for treatment. New 
HIV/AIDS drugs and therapies were being tested in medical research 
studies, but not available to the general public.109 Thus, HIV/AIDS 
medical research was viewed as “cutting-edge medical treatment” not 
“experimental research” that could cause serious harm.110 Consequently, 
some HIV/AIDS activists began to argue that medical research “served 
as an important means of access to otherwise unobtainable and theo-
retically helpful new therapies.”111 
Because in the 1990s the HIV/AIDS disease disproportionately aff-
ected vulnerable populations allegedly protected from the harms of 
medical research (women, minorities, and children), these vulnerable 
 
105. See Washington, supra note 2, at 271–98 (discussing research targeting 
black children). 
106. Ross, supra note 20, at 24. 
107. Yearby, supra note 15, at 23. It was also a result of the belief that children 
were therapeutic orphans. Id. 
108. Levine, supra note 1, at 108–09 (describing demands by individuals suffering 
from AIDS to participate in clinical drug trials with the hope of receiving a 
benefit).  
109. Sheryl L. Buske, Foster Children and Pediatric Clinical Trials: Access 
Without Protection is Not Enough, 14 Va. J. Soc. Pol’y & L. 253, 270 
(2007). 
110. Id. at 271. 
111. Steven Epstein, Inclusion: The Politics of Difference in Medical 
Research 63 (2007) (emphasis added). 
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populations, civil rights organizations, physicians, and researchers ad-
vocated for vulnerable populations’ right to participate in medical re-
search studies to gain access to potentially life-saving treatment.112 The 
argument for the need for inclusion was further bolstered by media 
reports that minorities and children lacked access to HIV/AIDS drug 
studies. 
For example, using National Institutes of Health (NIH) documents, 
a reporter noted in a front page Los Angeles Times article that African 
Americans, Latinos, and groups disproportionately afflicted with 
HIV/AIDS were significantly underrepresented in federally funded 
HIV/AIDS medical research studies.113 Advocates of inclusion also 
argued that children with HIV/AIDS in the United States did not 
receive AZT until three years after adults gained access to AZT because 
children were denied participation in medical research studies as a 
result of the Justice Principle.114 
This theory of inclusion is based on an incorrect assumption that 
economically disadvantaged minority children were not participating in 
medical research studies, including those related to HIV/AIDS. How-
ever, as discussed below, even once the Justice Principle was adopted 
in 1979, economically disadvantaged minority children were participat-
ing in medical research studies. 
B. Using Inclusion to Exploit 
In the late 1980s, researchers in Los Angeles gave healthy African 
American infants five hundred times the approved dose of an experi-
mental measles vaccine, which had already sickened and killed children 
in Senegal, Mexico, and Guinea-Bissau.115 This medical research study 
failed to provide any benefit to the population from which the subjects 
originated and unnecessarily exposed children to a risk researchers knew 
was harmful.116 
As discussed in Section I.A., in the 1990s, Kennedy Krieger Insti-
tute researchers investigating cheaper lead abate techniques partnered 
with landlords to partially abate lead tainted housing in Baltimore.117 
 
112. Levine, supra note 1, at 109. 
113. Epstein, supra note 111, at 61 (citing Robert Steinbrook, AIDS Trials Short-
change Minorities and Drug Users, L.A. Times (Sept. 25, 1989), https:// 
articles.latimes.com/1989-09-25/news/mn-175_1_aids-clinical-trials [https:// 
perma.cc/S6YT-FXVT]).  
114. Id. at 63.  
115. Washington, supra note 2, at 295. 
116. See id. (explaining that the vaccine was administered after the researches 
knew it would serve no benefit to the children because of the prior experi-
mental deaths in other countries).  
117. Grimes v. Kennedy Krieger Inst., Inc., 782 A.2d 807, 811–18 (Md. 2001). 
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In order to test the efficacy of the abatement procedures, the researchers 
in collaboration with the landlords ensured that only families with 
healthy children lived in the lead tainted housing by agreeing to pay for 
lead abatement procedures if the landlords rented to families with 
young children.118 Due to the socioeconomic status and racial makeup 
of the neighborhood, the young children participating in the study were 
all economically disadvantaged minorities.119 
Even though the information given to parents “implied that the 
study was protecting their children from lead damage and promised to 
inform parents of any hazards,”120 such as abnormal tests showing high 
lead levels, the study was non-therapeutic because it provided no ben-
efit to the participants.121 In fact, contrary to their promise, the re-
searchers did not notify the parents of their children’s elevated lead 
levels or lead hot spots in the house, so that the parents could protect 
their children from lead exposure.122 As a result, many of the healthy 
children suffered exposure to lead, which can cause inattention, irrita-
bility, hyperactivity, learning and reading delays, delayed growth and 
hearing loss, permanent brain damage, and even death.123 Thus, this 
study did not provide a benefit to the population from which the sub-
jects originated and unnecessarily exposed children to a risk researchers 
knew was harmful. 
From 1992 to 1997, researchers at the Columbia University’s 
Lowenstein Center for the Study and Prevention of Childhood 
Disruptive Behavior Disorders and New York City’s New York State 
Psychiatric Institute conducted research to try to show a link between 
genetics and violence, including only African American and Latino chi-
ldren as subjects.124 The researchers administered fenfluramine to 126 
boys between the ages of six and ten, even though the drug had already 
been shown to cause heart-valve damages, pulmonary hypertension (a 
life threatening form of high blood pressure), brain damage, and death 
in adults, unnecessarily exposing children to a risk researchers knew 
was harmful.125  
As a result of their inclusion in the study, the children were exposed 
to the same risks of physical harm the adults suffered who were pre-
 
118. Id. at 811–12. 
119. Id. at 812. 
120. Washington, supra note 2, at 292. 
121. Grimes, 782 A.2d at 811–12 n.2.  
122. Id. at 825. 
123. Lead Exposure in Children, supra note 32. 
124. Washington, supra note 2, at 272. 
125. Id. at 272–75. 
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viously administered fenfluramine, including but not limited to “an-
xiety, fatigue, headache, lightheadedness, difficulty concentrating, vi-
sual impairment, diarrhea, and nausea.”126 No generalizable knowledge 
was obtained from this study because the premise of the research that 
genetics was linked with violence had been disproven by over a century 
of research, and thus, the research was not using procedures that were 
consistent with sound research design.127 Furthermore, the researchers’ 
use of only minorities in the study, even though Caucasians also commit 
acts of violence, sent the message that minorities are more violent than 
Caucasians and thus must be studied.128 Hence, the research exploited 
the children for a medical research study that unnecessarily exposed 
children to a risk researchers knew was harmful, unfairly labeled them 
as more violent than Caucasians, and provided no generalizable knowl-
edge because the procedures that were used were not consistent with 
sound research design. 
These studies are not outliers. In fact, Harriet Washington’s sem-
inal book, Medical Apartheid, shows that economically disadvantaged 
minority children have still been exploited in medical research studies 
after the creation and implementation of the Justice Principle.129 Even 
when included in medical research studies conducted to find drugs for 
use in children, many economically disadvantaged children are still used 
for medical research studies that unnecessarily exposed children to a 
risk researchers knew was harmful and provided no benefit for the pop-
ulation from which they originate. 
For instance, for thirteen years (1988–2001), Illinois, Louisiana, 
Maryland, New York, North Carolina, Colorado, and Texas enrolled 
foster children between the age of three months to nineteen years old 
in Phase I and II drug studies for the treatment of the HIV/AIDS.130 
The majority of the foster children used for the study were economically 
disadvantaged minorities.131 The studies were conducted to determine 
 
126. Id. at 275.  
127. Id. at 275–76. 
128. Id. at 277–78. 
129. Id. at 236–37, 284, 294–95. 
130. John Solomon, Government Tested AIDS Drugs on Foster Kids, NBC News 
(May 4, 2005, 5:30 PM), http://www.nbcnews.com/id/7736157/ns/health-
aids/t/government-tested-aids-drugs-foster-kids/#.WKe29RLaeT8 [https:// 
perma.cc/6UQG-NH45]. The medical research tested various different drugs 
including protease inhibitors, Ritonavir therapy, and the live-attenuated 
Varicella vaccine. See Letter from Karen Cooper, Compliance Oversight 
Coordinator, Office for Human Research Prots., to Harvey R. Colten, Vice 
President and Senior Assoc. Dean, Columbia Univ. Medical Ctr., and Laura 
L. Forese, Vice President and Chief Medical Officer, N.Y. Presbyterian Hosp. 
(May 23, 2005) (on file with author) (describing findings of the OHRP review). 
131. Solomon, supra note 130. 
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the drug toxicity and adverse side effects of drugs that had not been 
shown to be safe in adults.132 Advocates of the research have argued 
that the inclusion of these children in the research benefited economi-
cally disadvantaged minority children by increasing their access to new 
and effective HIV/AIDS drugs.133 Notwithstanding this assertion, 
OHRP investigated the use of economically disadvantaged minority 
children in these HIV/AIDS drug studies and found that their use in 
many of these studies was inequitable and violated the Justice Prin-
ciple.134 
Seventeen years after the HIV/AIDS drugs studies started, OHRP 
issued a letter to the head of the IRB at Columbia University Medical 
Center, noting that some of the HIV/AIDS drug studies conducted at 
Columbia University Medical Center violated the law.135 Specifically, 
the IRB approved research protocols in which researchers had inequi-
tably used economically disadvantaged minority children in foster care 
to participate in the studies. In 2006, OHRP sent letters of violation to 
eighteen other universities conducting HIV/AIDS drug studies.136 Each 
 
132. Id. 
133. See Levine, supra note 1, at 117 (noting that “[b]ecause many of the potential 
child subjects for HIV/AIDS research are in foster care, their opportunities for 
participation have been severely limited by the lack of state or agency poli-
cies and the reluctance of agency officials to approve the entry of children 
into trials”). 
134. Letter from Karen Cooper, supra note 130. There was also an issue of targeting 
the children because of their manipulability and compromised position. See 
Yearby, supra note 15, at 30 n.155 (“In addition to this subjection of 
economically disadvantaged minority children to hazardous drug trials, some 
researchers failed to obtain proper consent from participa[nts] in the trials. 
There were two common practices that violated the informed consent laws. 
First, five children participating in the New York drug trials between five 
and ten years of age were asked to sign consent forms once they were told of 
the risks and benefits. Second, many of the researchers failed to obtain con-
sent from an authorized person, such as an independent advocate, for each 
child. The only consent that researchers obtained for participating foster child-
ren were blanket consents from child welfare agencies. None of the 200 Illinois 
foster children were appointed independent monitors even though researchers 
signed a document guaranteeing ‘the appointment of an advocate for each 
individual ward participating in the respective medical research.’ In New York, 
monitors were only appointed to one-third of the 465 foster children partici-
pating in the medical research studies.”) (quoting Solomon, supra note 130). 
135. Letter from Karen Cooper, supra note 130. 
136. See, e.g., Letter from Julia Gorey, Div. of Compliance Oversight, Office of 
Human Ressearch Prots., to Ronald R. Peterson, President of Johns 
Hopkins/Johns Hopkins Health Sys. (Feb. 17, 2006) (on file with author) 
(explaining the indicators of the university’s “noncompliance with [HHS] 
regulations for the protection of human research subjects,” with reference to 
certain research projects). The following institutions received similar letters 
determining that they had selected foster children inequitably: Bellevue 
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letter noted that the universities had used economically disadvantaged 
minority foster children in violation of the Justice Principle and 45 
C.F.R. § 46.111(a)(3).137 
Nevertheless, OHRP did not put an end to the studies, did not 
impose any sanctions, and its findings failed to directly address the 
actions of the researchers who violated the Justice Principle.138 Conse-
quently, the researchers who conducted the studies were able to publish 
their findings in main medical journals without repercussion. In issuing 
its findings, OHRP did not even explain why they found that the stu-
dies using economically disadvantaged minority children as research 
subjects violated the Justice Principle, but I suggest several reasons. 
First, it was not clear at the time of the studies that minority foster 
children were one of the populations suffering from HIV/AIDS.139 Thus, 
participation in the studies was not a benefit to the population. In fact, 
the minority foster children included in the HIV/AIDS drug studies 
were not even adequately tested for HIV/AIDS.140 The States gave blan-
ket consent for the use of these children instead of reviewing the files 
of each child to see if the child was infected with HIV/AIDS.141 Thus, 
 
Hospital Center, Bronx-Lebanon Hospital Center, Children’s Hospital Associ-
ation, Children’s Hospital of King’s Daughters, Children’s Hospital of Phila-
delphia, Children’s Hospital and Research Center at Oakland, Children’s 
Hospital and Regional Medical Center, Columbia University Medical Center, 
Cook County Bureau of Health Services, Drexel University College of Med-
icine, Duke University School of Medicine, SUNY Health Science Center, 
Stony Brook, SUNY Upstate Medical University, Universidad Central del 
Caribe, University of Chicago, University of Maryland Baltimore School of 
Medicine, University of Medicine and Dentistry of New Jersey, and University 
of Miami. See Letters from the Office for Human Research Prots. (on file 
with author). 
137. See supra note 136 and accompanying text. 
138. Id. 
139.  Letter from Vera Hassner Sharav, President, Alliance for Human Research 
Prot., to Dr. Michael Carome, Chief of Compliance, Office of Human Re-
search Prots., David Horowitz, Dir., Office of Compliance, Food & Drug 
Admin. (Mar. 10 2004), http://ahrp.org/complaint-phase-i-aids-drugvaccine-
experiment-on-foster-children/ [https://perma.cc/G2JH-2B4R]. 
140. Solomon, supra note 130; see also Sharav, supra note 139 (explaining that a 
false positive is possible in young infants with HIV-positive mothers because 
“in the uninfected infant, passively acquired maternal lgG antibodies disappear 
on average in 7 to 10 months, but may occasionally persist until 18 months. 
Therefore, a positive HIV antibody test in the young infant merely confirms 
maternal HIV infection but is not diagnostic for HIV infection specific to the 
infant.” (citing New York State Department of Health (DOH), Clinical Care 
of Adolescents and Children with HIV Infection: HIV Testing and Diagnosis, 
Hivdent, http://www.hivdent.org/_pediatrics_/dohdoh11/1section1iii.htm 
[https://perma.cc/YJP6-23YY] (last visited Apr. 27, 2017))). 
141. Sharav, supra note 139. 
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it can be argued that the children were selected simply “because of their 
easy availability, their compromised position, or their manipulability, 
rather than for reasons directly related to the problem being studied.”142 
Second, the children were public wards and according to the Justice 
Principle, researchers are not allowed to use the economically disad-
vantaged, who rely on public funds for health care, to be used as re-
search subjects for publicly funded research because they are already 
overburdened and unlikely to benefit as a population from the re-
search.143 
Third, the healthy children were unnecessarily “exposed . . . to the 
risks of medical research and drugs that were known to have serious 
side effects in adults and for which the safety for children was un-
known.”144 The drugs tested were failed cancer drugs that had severe 
side effects including “rashes, vomiting and sharp drops in infection-
fighting blood cells,” and death.145 Hence, yet again, healthy minority 
children were subjected to unnecessary risks that researchers knew were 
harmful. 
The dangers of participation in these studies for healthy children 
are best illustrated by an Illinois study of dapsone, a drug to prevent 
AIDS-related pneumonia.146 “Researchers reported that some children 
had to be taken off the drug because of ‘serious toxicity,’ others devel-
oped rashes, and the rates of death and blood toxicity were significantly 
higher in children who took the medicine daily, rather than weekly.”147 
The researchers noted that for the period of the study “[a]t least 10 
children died from a variety of causes, including four from blood poi-
soning, and researchers said they were unable to determine a safe, useful 
dosage. They said the deaths didn’t appear to be ‘directly attributable’ 
to dapsone but nonetheless were ‘disturbing.’”148 
Finally, research shows that not only did some of these healthy 
children experience long-term disability or die as a result of their par-
ticipation in these studies,149 but also it shows that many economically 
disadvantaged minority children in the United States still do not have 
 
142. Belmont Report, supra note 5, at 23,194. 
143. Id. at 23,196–97. 
144. Solomon, supra note 130. 
145. Id.  
146. Id.  
147. Id. 
148. Id. (emphasis added). This was not the only clinical trial in which death was 
a side effect of the drugs. “In one study, researchers reported a ‘disturbing’ 
higher death rate among children who took higher doses of a drug. That 
study was unable to determine a safe and effective dosage.” Id. 
149. Id.  
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access to this medicine.150 The studies did not provide a benefit to eco-
nomically disadvantaged children because structural and institutional 
racial biases limit their access to health care and medicine. 
C. Bias in Health Care 
Structural racial bias operates at the societal level, denying some 
groups access to the resources of society, while privileging other 
groups.151 “Institutional [racial] bias operates through organizational 
structures and establishes ‘separate and independent’ barriers through 
the neutral denial of access to quality health care that results from the 
normal operations of the institutions in a society.”152 Although most 
research on structural and institutional racial biases within the health 
care system focuses on adults, it is clear that when these adults have 
children, the biases also impact their children’s access to health care.153 
I will discuss how these biases that affect adults impact their children 
and where available, I will discuss research that has directly focused on 
children. 
1. Structural Racial Bias 
“Structural racial bias is a result of ‘power relationships that exist 
between racial and socioeconomic groups, where [one] dominant group[] 
holds power over [the] other[] [group] and use[s] that power to secure 
 
150. See Am. Acad. of Pediatrics, Comm. on Pediatric AIDS, Section on Int’l 
Child Health, Policy Statement: Increasing Antiretrovial Drug Access for 
Children with HIV Infection, 119 Pediatrics 838, 838–39 (2007) (explaining 
that “there are numerous barriers to delivery of [Antiretroviral Therapy] to 
children in resource-limited settings”); Sarah Childress, Why Some with HIV 
Still Can’t Get Treatment, PBS (July 11, 2012), http://www.pbs.org/ 
wgbh/pages/frontline/social-issues/endgame-aids-in-black-america/why-
some-with-hiv-still-cant-get-treatment/ [https://perma.cc/H8H8-TG7H] (ex-
plaining that one primary reason Americans are not receiving treatment for 
HIV is that they cannot afford it). 
151. Mullings & Schulz, supra note 69, at 12. See also René Bowser, Racial 
Profiling in Health Care: An Institutional Analysis of Medical Treatment 
Disparities, 7 Mich. J. Race & L. 79, 85 (2001) (finding that racial bias 
causes “racial disparities [to] exist across a spectrum of health care settings 
and cover[s] a host of diseases”). 
152.  Ruqaiijah Yearby, Racial Disparities in Health Status and Accessing Health 
Care, in Debates on U.S. Healthcare 78, 83 (Jennie Jacobs Kronenfeld 
et al. eds., 2012). 
153. Children’s Health Disparities are not often studied, which is why Ivor Braden 
Horn of the Children’s National Medical Center and Anne C. Beal of The 
Commonwealth Fund wrote an article calling for the framing of a research 
agenda for studying child health disparities. See generally Ivor B. Horn & 
Anne C. Beal, Child Health Disparities: Framing a Research Agenda, 4 
Ambulatory Pediatrics 269 (2004) (providing a framework for research 
on child health care disparities). 
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material and social resources such as income [and] wealth.’”154 The 
dominant group remains in power “because [its] position in society en-
ables [it to retain power] despite the will or aims of [the groups it] has 
power over.”155 In health care, structural bias is the delivery of health 
care based on ability to pay. 
As a result of this bias, “those with privilege, such as wealthy Cau-
casians, . . . obtain the best quality health care available.”156 The 
privileged obtain access because they are able to afford health insurance 
or pay for health care not covered by insurance. Those without privi-
lege, such as minorities and the economically disadvantaged, have limi-
ted access to health care because they do not have health insurance or 
they cannot afford to pay for health care.157 For instance, “African Am-
ericans and Hispanics are more likely than Caucasians to work in low-
wage jobs, and tend to have reduced access to employer-sponsored cov-
erage relative to their higher-wage counterparts.”158 This directly affects 
the health care of African American and Hispanic children. 
For example, most union-represented housekeeping, maintenance, 
and other service workers at the Johns Hopkins Hospital are paid under 
$14.91 per hour, leaving them below the poverty level.159 As a result of 
the low pay, their children are uninsured or on Medicaid because they 
cannot afford to purchase Hopkins health insurance.160 Consequently, 
minority children and adults are more likely than Caucasians to be 
uninsured. This has not changed with the passage of the ACA. 
In the first open enrollment period of the ACA (2013–2014), the 
percentage rates of uninsured fell significantly for economically dis-
advantaged adults (from 35% to 24%) and Hispanics (from 36% to 
23%).161 In 2014, thirty-three million people (10.4%) were without 
 
154. Ruqaiijah Yearby, Racial Inequities in Mortality and Access to Health Care: 
The Untold Peril of Rationing Health Care in the United States, 32 J. of 
Legal Med. 77, 87 (2011) (citations omitted). 
155. Id.  
156.  Id.  
157. Id. at 80.  
158. Id. at 83. 
159.  Fern Shen, Johns Hopkins Hospital Workers Protest “Poverty Wage” Pay 
Scale, Baltimore Brew (April 1, 2014), https://www.baltimorebrew 
.com/2014/04/01/johns-hopkins-hospital-workers-protest-poverty-wage-pay-
scale/ [https://perma.cc/KAC7-N6UM]. 
160. Id.  
161. New Survey: After First ACA Enrollment Period, Uninsured Rate Dropped 
from 20 Percent to 15 Percent; Largest Declines Among Young Adults, 
Latinos, and Low-Income People, The Commonwealth Fund (July 10, 
2014), http://www.commonwealthfund.org/publications/press-releases/2014/ 
jul/after-first-aca-enrollment-period [https://perma.cc/32AL-SNUW]. 
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health insurance.162 In 2014, employment-based health insurance cover-
ed 55.4% of the U.S. population, Medicaid covered 19.5% of the U.S. 
population, Medicare covered 16% of the U.S. population, direct-
purchase health care covered 14.6% of the U.S. population, and military 
health care covered 4.5% of the U.S. population.163 Nevertheless, minori-
ties and the economically disadvantaged still remain uninsured at a 
higher rate than those who are privileged because of the failure of those 
in power in nineteen states to expand Medicaid coverage.  
As of January 2016, Washington, DC and thirty-one states have 
expanded Medicaid to cover economically disadvantaged adults. How-
ever, in the nineteen states that did not expand Medicaid, the econo-
mically disadvantaged remain without health insurance because their 
employer does not provide coverage, they earn too much to qualify for 
Medicaid, and they do not earn enough to qualify for tax credits to 
purchase health insurance on their own.164 Approximately three million 
economically disadvantaged adults remain uninsured because of the 
failure to expand Medicaid, and they reside in states with the largest 
uninsured population such as Texas, Florida, Georgia, and North 
Carolina.165 
More than sixty percent of the economically disadvantaged, who 
are in a family with a worker, remain uninsured because of the failure 
to expand Medicaid.166 They work in part-time jobs, jobs for employers 
with less than fifty employees (so not covered by the ACA penalties), 
or jobs that do not provide health insurance like those in the agriculture 
and service industries.167 Because minorities are more likely to work in 
these industries and live in families with lower incomes than Cau-
casians, they disproportionately remain uninsured due to the failure to 
 
162. Jessica C. Smith & Carla Medalia, Health Insurance Coverage in the 
United States: 2014, Current Population Reports, U.S. Census Bureau 
3 (Sept. 2015), https://www.census.gov/content/dam/Census/library/ 
publications/2015/demo/p60-253.pdf [https://perma.cc/JWD7-G4BV]. 
163. Id.  
164. Id.  
165. Rachel Garfield & Anthony Damico, The Coverage Gap: Uninsured Poor 
Adults in States that Do Not Expand Medicaid, Kaiser Family Found. 2 
(Oct. 19, 2016), http://kff.org/uninsured/issue-brief/the-coverage-gap-
uninsured-poor-adults-in-states-that-do-not-expand-medicaid/ [https://perma 
.cc/KQA5-QJ2A].  
166. Id. at 4.  
167. Id.  
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expand Medicaid.168 In fact, minorities make up over half of the un-
insured, while only accounting for forty percent of the U.S. popula-
tion.169 This affects children as well. 
Before the ACA, an estimated eight million children were unin-
sured.170 The three states with the highest number of uninsured children 
were Texas (21.4%), Florida (19.2%), and New Mexico (15.5%).171 Since 
the passage of the ACA, an estimated five million children remain un-
insured.172 Although the federal government partners with states under 
Medicaid and the Children’s Health Insurance Plan to provide health 
insurance for nearly forty percent of all economically disadvantaged 
children, minority children are still more likely to be uninsured than 
Caucasian children.173 These uninsured children are more likely to live 
in low-income families and almost a quarter of them are in fair or poor 
health.174 Moreover, earlier studies have shown that “uninsured children 
are also more likely . . . to have gone without needed medical, dental, 
or other health care . . . . [and they are] more likely to rely on the 
emergency room as their usual source of care.”175 Lack of insurance also 
results in lack of access to prescription medicine.176 A poignant example 
of how structural racial bias affects economically disadvantaged child-
ren access to health care is the Deamonte Driver story. 
Deamonte Driver, an African American male youth, died of a toot-
hache because he did not have health insurance and so he never received 
a routine $80 tooth extraction that may have saved him.177 Deamonte 
 
168. Id. at 2.  
169. Rachel Garfield et al., The Uninsured: A Primer, Kaiser Family Found. 
9 (Nov. 2016), http://files.kff.org/attachment/Report-The-Uninsured-A%20 
Primer-Key-Facts-about-Health-Insurance-and-the-Unisured-in-America-in-
the-Era-of-Health-Reform [https://perma.cc/6CZB-X9MM]. 
170. James A. Baker III Inst. for Pub. Pol’y of Rice Univ., The Economic 
Impact of Uninsured Children on America, 40 Baker Inst. Policy Rep., 
no. 40, June 2009, at 2, http://www.bakerinstitute.org/media/files/ 
Research/6db8160c/HPF-pub-HoShortUninsuredChildren-060309.pdf [https: 
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Driver’s family was no different than most working poor families. His 
mother worked several jobs, but none provided insurance, or paid 
enough for the family to buy insurance.178 Deamonte was covered under 
Medicaid, which covers oral health services.179 However, he never receiv-
ed the dental care he needed because there was a shortage of dentists 
willing to treat Medicaid patients or those who cannot afford to pay for 
health care.180 By the time his mother was able to locate a dentist will-
ing to take Medicaid, Deamonte was no longer covered by Medicaid 
and thus did not receive treatment.181 
Lacking health insurance, Deamonte received all of his care in an 
emergency room or hospital.182 Instead of a tooth extraction, his care 
included two brain surgeries, six weeks of hospitalization, and physical 
and occupational therapy, totaling $250,000.183 On his last day, 
Deamonte played cards and watched a show on television with his mo-
ther.184 When he called her later that evening, Deamonte said, “Make 
sure you pray before you go to sleep.”185 The next morning, Deamonte 
was dead from a brain infection caused by the spread of the bacteria 
from the abscess in his mouth.186 Deamonte did not have to die; he was 
only a twelve-year-old boy with a cavity. He died because health care 
in the United States is provided based on ability to pay, not medical 
need. Deamonte’s death is not an outlier. In fact, a research study con-
ducted by Johns Hopkins Children’s Center found that uninsured child-
ren faced a sixty percent increased risk of dying than insured children.187 
Even if economically disadvantaged minority children are covered 
by Medicaid, this does not guarantee them access to medical and dental 
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care. Research shows that Medicaid patients have a difficult time acc-
essing health care because Medicaid reimbursement rates are so low.188 
In fact, numerous states, including California, Florida, Illinois, Massa-
chusetts, and Texas, have been sued for failing to provide children with 
early and periodic screening, diagnosis, and treatment.189 Moreover, 
when minorities and the economically disadvantaged obtain private 
health insurance, they still lack access to health care because they are 
underinsured, meaning they have to pay high deductibles or out of 
pocket for medical costs. 
According to a Commonwealth Fund report, in 2014 over thirty-
one million people were underinsured, about twenty-three percent of 
those with year-round health insurance.190 Of the underinsurance, forty-
four percent reported forgoing care because of the cost, and fifty-one 
percent reported having problems paying medical bills or debts, totaling 
$4,000 or more.191 People with low incomes under 200% of the federal 
poverty line accounted for sixty-one percent of underinsured adults in 
the U.S.192 By 2015, the U.S. Census bureau reported that 46.2 million 
people (14.7%) were in poverty in the United States.193 The poverty 
rate has increased from 2007–2011, when the U.S. Census bureau re-
ported that 42.7 million people (14.3%) had incomes below the poverty 
line.194 The rate of poverty for African Americans was 25.8% and 23.2% 
for Hispanics compared to 11.6% for Caucasians.195 
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Adding insult to injury, the wealthy, who predominantly have 
health insurance, receive discounts on the cost of health care, negotiated 
by their insurers, while minorities and the economically disadvantaged, 
who do not generally have health insurance or are underinsured, are 
charged more for the health care services they receive and are increas-
ingly required to pay upfront for the care they receive.196 Under the 
ACA,197 nonprofit hospitals can no longer charge uninsured patients 
more than they generally bill insured patients for emergency and other 
medically necessary care.198 Unfortunately, this still leaves the unin-
sured unprotected because the policy does not apply to for-profit hos-
pitals, which account for up to one fifth of all hospitals in the U.S.199 
Additionally, it still leaves it up to the nonprofit hospital to determine 
who qualifies for charity care, which as discussed in Subsection 2, the 
hospital may not extend to everyone who qualifies. 
Additionally, the ACA does not equalize the care provided to mi-
norities or the economically disadvantaged when compared to the 
wealthy. A 2012 New York Times article noted that affluent patients, 
who pay in cash, can stay in elite hospital wings that offer marble baths, 
butler service, and bed linens by “Frette, Italian purveyors of high-
thread-count sheets [sold] to popes and princes.”200 Yet, the article no-
ted that one patient who could not afford the elite rooms was left in 
pain, on a gurney, without a bedpan.201 
Unequal treatment affects children as well. “[A] study of 965 child-
ren with acute asthma who were treated in emergency departments 
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found that uninsured children consistently received lower quality of care 
than insured children.”202 Institutional bias also prevents access to 
health care for these groups, because health care institutions are allowed 
to decide what hospitals to close and who qualifies for charity care. 
2. Institutional Racial Bias 
Examples of institutional racial bias within the health care system 
include hospital closures in minority neighborhoods and lawsuits a-
gainst the economically disadvantaged for unpaid care. Both further 
limit access to health care for economically disadvantaged minority 
children. Not all actions by an institution that disproportionately affect 
minorities and the economically disadvantaged are biased. In order to 
constitute institutional bias, the action must reinforce the racial and/or 
class hierarchy and impose substantial harm on minorities and the eco-
nomically disadvantaged. Once this occurs, then the institution’s act-
ions constitute institutional bias even if the actions are seemingly neu-
tral.203 
Shortly after the passage of the Civil Rights Act of 1964, hospitals 
in African American communities closed and relocated to affluent Cau-
casian neighborhoods.204 This still continues. In 1992, a report of 190 
urban community hospitals between 1980 and 1987 found that the per-
centage of African American residents in the neighborhood was the 
most significant factor in hospital closures.205 In 2006, Alan Sager re-
ported that as the African American population in a neighborhood in-
creased, the closure and relocation of hospital services increased for 
every period between 1980 and 2003, except between 1990 and 1997.206 
Hence, research shows that as the percentage of African American resi-
dents increases in the neighborhood, hospital closures increase. 
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In fact, Dr. Sager has shown that forty-five percent of hospitals 
open in 1970 had closed by 2010, and of these hospitals sixty percent 
were in neighborhoods that were predominately African American.207 
St. Louis and Detroit are poignant examples of these race-based hos-
pital closures. St. Louis had eighteen hospitals in predominately African 
American neighborhoods. By 2010, all but one had closed.208 In 1960, 
Detroit had forty-two hospitals open in predominately African Amer-
ican neighborhoods; by 2010 only four were open.209 
This reduction of hospital beds in African American communities, 
which generally have the greatest need for care, further compromises 
African Americans’ health by decreasing their access to health care 
thereby increasing health care costs.210 As hospitals leave predominately 
African American neighborhoods, the remaining hospitals are left to fill 
the void. This often strains the remaining hospitals’ resources and their 
ability to provide quality care. Consequently, the hospitals that do 
remain to provide care to African Americans gradually deteriorate and 
provide substandard care.211 
Not only is access to health care diminished because of a reduction 
of hospital services, but care also suffers because of physician 
departures.212 Once a hospital has closed or relocated, the physicians 
practicing in the area often follow the hospital to more affluent neigh-
borhoods, thereby further disrupting the health care services in pre-
dominately African American neighborhoods.213 Evidence shows that 
primary care physicians often leave after the closure of a neighborhood 
hospital because the hospital provides a critical base for their 
practice.214 This disruption in care is significant because many 
predominately African American neighborhoods already suffer from 
physician shortages prior to hospital closures and physician flight.215 As 
the number of primary care physicians decreases, African Americans 
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are forced to seek care in emergency rooms and public hospitals, which 
are often understaffed and not adequately maintained.216 Thus, the 
institutional decision to close hospitals in predominately African 
American neighborhoods substantially harms African Americans and 
reinforces the racial hierarchy that African American lives do not 
matter. 
In addition to the lack of health care services available in minority 
neighborhoods, some nonprofit hospitals erect barriers to care for the 
economically disadvantaged by suing them for unpaid medical bills.217 
These practices have continued even after the passage of the ACA, 
which tried to limit these aggressive collection practices.218 Numerous 
nonprofit hospitals in Ohio, Minnesota, Missouri, New York, North 
Carolina, and Texas, have sued patients for unpaid bills, even though 
many of the patients are economically disadvantaged and could qualify 
for charity care, which would discharge their bills.219 
For example, in North Carolina, nonprofit hospitals have filed more 
than 40,000 collection lawsuits in a five-year period.220 Carolinas 
HealthCare system, a nonprofit health care system, has filed over 12,000 
lawsuits in a five-year period, while having over $150 million in annual 
profits and enjoying $100 million in tax breaks.221 Many of the patients 
who were sued for unpaid bills were uninsured and were economically 
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disadvantaged.222 Once the hospital wins the case and receives a judg-
ment against the patient, it usually places a lien on the patient’s 
house.223 Due to the lawsuits, the economically disadvantaged patients 
cannot sell their homes, are pushed further below the poverty line, have 
their credit report scores decline, and forgo medical care because they 
are worried about future wage garnishments and liens being placed on 
their homes. This substantially harms them and reinforces the class 
hierarchy that the lives of the economically disadvantaged do not 
matter. 
Due to structural and institutional racial biases within the health 
care system, minorities and the economically disadvantaged lack access 
to medicine and health care because they are uninsured, underinsured, 
or unable to pay for health care. As a result of forgoing health care, 
minorities and the economically disadvantaged are often more likely to 
be disabled or in poor health and vulnerable to inducements to partici-
pate in medical research to obtain access to health care. However, be-
cause of structural and institutional racial biases, once the medical re-
search studies end, minorities and the economically disadvantaged do 
not receive the benefit of the studies because they cannot afford the 
medicine and lack access to health care. 
D. The Effect of Bias on Medical Research 
Researchers from health care institutions that deny minorities and 
the economically disadvantaged access to health care use these same 
populations as subjects for medical research studies. In fact, empirical 
data shows that in comparison with their percentage in the U.S. census, 
African American children continue to be overrepresented in non-
therapeutic medical research studies and underrepresented in Phase III 
therapeutic medical research studies.224 
This means that when compared to Caucasians, African American 
children participate in medical research studies that may or may not 
add to scientific knowledge that benefits the general society, but not in 
medical research studies that will be beneficial for them as a group. The 
literature suggests that the reason for this overrepresentation in non-
therapeutic medical research studies is that African American children 
are overrepresented in economically disadvantaged neighborhoods, 
which house the academic medical centers that conduct medical re-
search studies.225 Thus, African American children are included in med-
ical research studies because of their proximity to the academic medical 
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centers, not because the research addresses their populations’ health 
needs. Researchers who conduct medical research studies using econo-
mically disadvantaged minority children are often affiliated with health 
care institutions that prevent access to health care for economically 
disadvantaged minority children. 
Although there is little research regarding how institutional deci-
sions affect children’s access to health care, it is clear that institutional 
decisions limit access to health care for the economically disadvantaged 
and minority adults. This can have an indirect effect on children if the 
patients denied care are their parents. For example, Heartland Regional 
Medical Center, a nonprofit hospital in Missouri that receives tax 
breaks in exchange for providing care to the economically disadvant-
aged, has sued approximately 6,000 patients for unpaid bills from 2009–
2013, even though some of the patients should have qualified to have 
their bills forgiven.226 Once the hospital wins the case and receives a 
judgment against the patient, it is allowed to garnish the patient’s 
wages—and if the state allows it, the hospital can also charge the pa-
tient interest on her bill.227 
The hospital has also taken liens out on a patient’s home to recoup 
the costs of any judgments exceeding $1,000.228 In 2013, the hospital 
made $605 million in gross revenues, $45 million of which was profit, 
yet it filed over 2,200 lawsuits for medical debts.229 Garnishments 
amount to one-half of one percent of the hospital’s revenues.230 As a 
result of these institutionally biased practices, many economically dis-
advantaged patients cannot sell their homes, are pushed further below 
the poverty line, have their credit report scores decline, and forgo med-
ical care for themselves and their children because they are worried 
about future wage garnishments and liens being placed on their homes. 
Notwithstanding the lawsuits filed to collect unpaid hospital bills from 
the uninsured and economically disadvantaged, Heartland Regional 
Medical Center recruits some of these patients to participate in the 
medical research studies, which offer access to free health care only 
when the subject is participating in the medical research study.  
In addition to the financial barriers to care, many hospitals refuse 
to treat certain uninsured and economically disadvantaged patients, 
often redirecting them to community hospitals or clinics, while using 
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them as research subjects in medical research. The University of Chi-
cago Medical Center (Center) is a perfect example of this tension be-
tween denying care to minorities and the economically disadvantaged, 
while focusing on expanding medical research studies using these pop-
ulations. In 2009, the Center adopted policies to redirect people, suff-
ering from non-urgent injuries and illnesses, who lived in the neigh-
borhoods surrounding the hospital, elsewhere to community hospitals 
and clinics.231 Because the hospital is located in an economically disad-
vantaged area that is racially segregated, the people being redirected 
were disproportionately disadvantaged minorities. However, when the 
Center needed subjects for research, for studies, these people were so-
licited for participation in research because of their proximity to the 
hospital.232 
Denials of access to health care occur even when care is required. 
Under the Emergency Medical Treatment and Active Labor Act 
(EMTALA),233 hospitals are required to provide a screening examina-
tion to determine if a person is experiencing an emergency condition or 
in active labor.234 If the patient is experiencing an emergency condition 
or in active labor, the hospital, regardless of the patient’s ability to pay, 
is required to stabilize the patient, admit the patient, or complete an 
appropriate transfer to another facility.235 Unfortunately, some hospitals 
violate EMTALA by denying care to patients based on ability to pay, 
but then seek to use these same patients as medical research subjects. 
For instance, in 2009, the Center tried to limit the number of inpatient 
beds available to emergency room patients and failed to provide care 
to those with urgent care injuries.236 Although the policies were not fully 
implemented after two physician groups voiced their concerns, the hos-
pital still failed to provide care to patients with urgent care injuries and 
was fined $50,000 as a result of the death of a patient waiting in the 
emergency room.237 As discussed above, the Center still uses these peo-
ple in medical research studies. 
In the United States, structural and institutional racial biases pre-
vent economically disadvantaged minorities from accessing health care 
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and medicine. These biases allow institutions to bring lawsuits for un-
paid care and outright deny care because health care is delivered based 
on ability to pay, not need. Hence, even if economically disadvantaged 
minority children participate in a medical research study that finds a 
new treatment for a disease, the children will not have access to the 
treatment because structural and institutional racial biases prevent 
them from accessing the treatment once the study is completed. Thus, 
even if researchers have good intentions when they include economically 
disadvantaged minority children in medical research studies, it still may 
be exploitation, a violation of the Justice Principle, because the popul-
ation from which the subject originates will not benefit from the re-
search. 
III. Ensuring Justice Is Fulfilled 
Although arguments for inclusion were based on altruistic notions 
of providing everyone with a “fair opportunity” to participate in med-
ical research studies to obtain access to treatment, it ignores structural 
and institutional racial biases that limit economically disadvantaged 
minority children’s access to health care and treatment after the med-
ical research study ends, preventing them from benefiting from partici-
pation in medical research. In order to prevent exploitation of economi-
cally disadvantaged minority children, I suggest that the Justice Prin-
ciple incorporate the Human Development Approach, which demands 
that researchers provide a benefit to the population from which the 
subjects originated that alleviates some of the population’s underlying 
problems, such as lack of access to health care. To ensure that there is 
a benefit that will alleviate some of the population’s underlying pro-
blems, I propose the use of the Vulnerability and Equity Impact Assess-
ment (VEIA) tool, which I created based on the Health Equity Impact 
Assessment (HEIA) tool.238 
Under the VEIA, the researcher must complete an introspective 
summary of their research that includes the purpose of the research, 
those affected by the condition being studied, whether the research is a 
priority to those affected with the condition, and pinpoint any dis-
parities (age, racial, or class based) in the treatment of the condition. 
After completing this summary, researchers need to identify the struc-
tural and institutional racial biases that prevent economically disad-
vantaged minority children from accessing health care, the adverse 
impacts economically disadvantaged minority children will suffer as a 
result of their participation in the research, and whether participation 
in the medical research study will alleviate structural and institutional 
racial biases. If researchers determine that because of their status (age, 
social class, race) economically disadvantaged minority children are 
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overburdened, then the researchers cannot use the children as research 
subjects. 
Using the VEIA, a newly created Board of Children (Board for 
Children or the Board) would be responsible for approving all medical 
research studies seeking U.S. government funding that plan to use 
children. The completed tool should be posted on clinicaltrials.gov and 
used by the Board to determine if the researcher was fulfilling the 
benefit requirement of the Justice Principle. Redefining Justice to in-
clude the Human Development Approach, implementing the VEIA, and 
having the Board complete the VEIA before certifying research will 
begin to address the structural and institutional racial biases that lead 
to exploitation. 
A. Ending Exploitation: Human Development Approach 
Although originally couched in terms of global justice, the time has 
come to apply the Human Development Approach to medical research 
conducted in the United States on populations that suffer the same 
social and economic disadvantages as those in the developing world. 
This Approach offers insightful guidance on how to prevent the exploi-
tation of economically disadvantaged minority children participating in 
medical research studies conducted in the United States. 
1. Theory 
The Human Development Approach is a means to combat the 
“minimalist view” that “accepts the status quo in the host community 
as the appropriate ‘normative baseline’ against which proposed research 
initiatives are evaluated—meaning that the status quo is treated as the 
threshold of a person’s moral entitlements in this particular sphere.”239 
Because the minimalist is only worried about doing no harm (Non-
maleficence) and providing a benefit (Beneficence), then the status quo 
allows him to avoid questions of distributive justice. The status quo 
allows the minimalist to view harm as any additional damage greater 
than the status quo caused to the research subject and a benefit as any 
gain. 
One example of the minimalist approach is the inclusion/fair opp-
ortunity theory that believes research is just if everyone is provided an 
opportunity to participate, regardless of whether the research will fur-
ther burden the most disadvantaged of the population or provide them 
with a direct benefit.240 The inclusion/fair opportunity theory cham-
pions leaving up to the discretion of the researchers and the host coun-
try to conclude what will benefit research subjects. However, this theory 
leaves little room to determine what is a meaningful benefit for the 
 
239. London, supra note 17, at 27. 
240. See id. at 25 (“The debate about justice has become synonymous with the 
question of who gets access to the fruits of successful research.”). 
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research subject, because the power balance remains with the researcher 
and host country, not the research subject.241 Notwithstanding this 
power imbalance, proponents of this theory believe that the host coun-
try can bargain for a host of benefits that are comparable or better than 
benefits given in developed countries.242 However, in reality, the re-
search subject is dependent on the charity of the researcher and the 
host country. 
This minimalist approach also favors “justice as mutual advan-
tage.”243 Proponents of the minimalist theory believe that researchers 
and research subjects receive a mutual advantage. Researchers obtain 
subjects and research participants receive bargained-for benefits. Yet, 
the Justice Principle is not about creating a mutual advantage; rather, 
it proscribes the duty researchers owe to their research subjects. As 
noted in the Belmont Report, the Justice Principle requires that re-
searchers have a duty to assess whether potential research subjects and 
the population from which they come will benefit from the research.244 
London notes that this duty flows from contractual and citizenship 
obligations.245 
Specifically, in developing countries, researchers contract with gov-
ernment officials to use their citizens for medical research studies.246 
However, the governments of some developing countries are often the 
cause of the poverty and poor health of their citizens. The failure to 
take this into consideration, and the broader social and economic con-
text in which the research takes place, eliminates the infomation ne-
cessary to determine whether the researcher is contracting with those 
who have caused the social and economic disadvantages of the research 
population.247 “These failures can generate prior moral claims that the 
community members have against their own authorities, and such 
claims may constrain the range of cooperative or collaborative relation-
ships in which researchers may permissibly engage.”248 By contracting 
with these governments, the researchers have become accomplices in 
 
241. See id. at 26 (“[D]etails about the level and type of benefit require value 
judgments that are best left to the discretion of those in the host com-
munity.”). 
242. Id. 
243. Id. at 25 (citation omitted). 
244. Belmont Report, supra note 5, at 23,194. 
245. London, supra note 17, at 30 (“[D]uties of rectification may attach to re-
searchers who work for or are funded by entities that have contributed more 
directly to the plight of developing world populations.”).  
246. Id. 
247. Id.  
248. Id. 
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the devastation of these populations. To rid themselves of complicity, 
researchers have a special contractual duty to aid the populations they 
are using for research.249 
Furthermore, as citizens of developed nations that have caused or 
facilitated the lack of access to health care and medicine in developing 
nations, the researchers have a duty to aid the populations they are 
using for research.250 London submits that “at the most general level 
duties of rectification may attach to all citizens of democratic nations 
whose policies and international activities have contributed to the pli-
ght of those in the developing world.”251 Policies that have contributed 
to the plight of those in the developing world, includes participation in 
the Agreement on Trade-Related Aspects of Intellectual Property 
Rights (TRIPS) agreement, which protects pharmaceutical companies’ 
intellectual property rights across the world.252 Even though TRIPS 
allows for countries to import or produce generic versions of some medi-
cines in cases of national emergency, United States pharmaceutical com-
panies have aggressively pressed for trade sanctions or instituted legal 
action under TRIPS that have blocked legitimate efforts to provide 
medicines to developing countries in cases of national emergencies, such 
as the HIV/AIDS epidemic.253 
This citizenship duty requires researchers to limit the use of indivi-
duals from developing countries to instances where the medical research 
studies will “expand the capacity of the host community’s basic social 
structures [] to meet the distinctive health priorities of that commun-
ity’s members . . . .”254 Only then is it permissible to use a developing 
nation’s scarce public resources for medical research studies.255 Thus, 
medical research is acceptable if it functions “as a part of a division of 
labor in which the distinctive scientific and statistical methods of the 
research enterprise target and investigate the means of filling the gaps 
between the most important health needs in a community and the 
 
249. Id. 
250. Id. 
251. Id. International activities that have contributed to the plight of individuals 
in developing nations also includes what Thomas Pogge calls “international 
resource privilege.” Id. This privilege is the ability to wrestle control away from 
legitimate developing country governments as a means to enrich the privileged 
few. Id. 
252. Id. See also Cynthia Ho, Access to Medicine in the Global Economy: 
International Agreements on Patent and Related Rights (Oxford 
Univ. Press, 2011) (discussing TRIPS and its effects on access to medicine). 
253. London, supra note 17, at 30. 
254. Id. at 33. 
255. Id.  
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capacity of its social structures to meet them.”256 To be just in develop-
ing countries, research “must directly and indirectly expand the capa-
city of the host community’s basic social structures either to meet the 
distinctive health priorities of that community’s members or to meet 
their basic health needs under distinctive social or environmental cir-
cumstances.”257 If the country does not have an appropriate structure 
available, then the researcher must work with community and inter-
national groups to create a structure.258 The structure must be sustain-
able, and thus the research should serve as the anchor for which addi-
tional long-term aid can be provided.259 
Clearly, the injustices suffered by those in developing nations are 
not the full responsibility of the researchers. However, by using the 
citizens of these nations for their own benefits, researchers and their 
institutions have a duty to provide the research subjects with a mean-
ingful benefit.260 The condition of providing sustainable social structures 
to improve health outcomes in the host community is not an onerous 
requirement.  
This condition is easily fulfilled, for example, when developed 
countries collaborate on research that targets a common problem. 
When doing research in developing nations, it might be fulfilled 
if researchers can find host communities in which the target of a 
research program represents a health priority and where the resul-
ting intervention could be implemented within the health struct-
ures of the host community.261  
Although couched in international terms, the Human Development 
Approach can also apply to the United States’s domestic problems of 
exploitation of economically disadvantaged children for the greater 
good. 
2. Human Development in the U.S. 
In the United States, researchers have the same contractual and 
citizenship obligations. In terms of contractual obligations, researchers 
in the United States have a duty to ensure that they are not contracting 
with those who have caused the social and economic disadvantages suff-
ered by the potential research subjects. More specifically, researchers 
 
256. Id. 
257. Id. 
258. Id. at 34. 
259. Id. at 33. 
260. Id.  
261. Id. at 35. 
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should not contract with those who have caused structural and institu-
tional racial biases to prevent economically disadvantaged minority 
children from accessing health care. For instance, researchers should 
not have contracted with states to enroll foster children in HIV/AIDS 
drug studies262 because, as discussed in Section II.C. and in more detail 
in subsection 1, states have failed to provide the children with adequate 
health insurance that would provide them with access to health care.263 
Furthermore, the states failed to test the children to ensure that they 
suffered from HIV/AIDS, unnecessarily exposing the children to risk.264 
The failures of the states to provide adequate health insurance and to 
test the children for HIV/AIDS creates prior moral claims that the 
children have against the states, which constrains the researchers’ abil-
ity to enter into a contract with the states. By contracting with the 
states, the researchers have become accomplices in the devastation of 
the children, which they can only rid themselves of by providing the 
children with a benefit that will alleviate some of their underlying 
problems. The researchers also have a citizenship duty. 
The citizenship duty is based on researchers’ affiliation with insti-
tutions or hospitals that have erected insurmountable barriers to access 
to health care for economically disadvantaged minority children. As 
discussed in Section II.D., health care institutions have sued econo-
mically disadvantaged patients who qualify for charity care and denied 
care to economically disadvantaged and minorities.265 However, when 
seeking subjects for their medical research studies these same institu-
tions seek out the same economically disadvantaged minority children 
they refused to treat. Denied access to health care, these economically 
disadvantaged minority children are willing to participate in medical 
research studies, even if access to health care is offered for a short dur-
ation of time. 
By denying economically disadvantaged minority children access to 
health care, these institutions are creating a vicious cycle that will not 
be fixed until these institutions are required to provide a benefit to the 
population of economically disadvantaged minority children that will 
alleviate some of their underlying problems. 
3. Applying the Approach to U.S. Research 
Some may argue that the HIV/AIDS drug studies did not violate 
the Justice Principle because although the children suffered serious side 
effects including death, the children were going to die anyway from 
 
262. Solomon, supra note 130. 
263. See supra note 189 (listing cases that involved challenges to the state for 
failure to access health care for child Medicaid recipients). 
264. Yearby, supra note 15, at 26, 32. 
265. See supra Part II.D.  
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HIV/AIDS, so there was no additional damage. Furthermore, the child-
ren gained a benefit because they were granted access to health care 
and investigational drugs during the study. This is the minimalist app-
roach.266 
The problem with researchers that use the minimalist approach is 
they only use morally relevant information regarding the social and 
economic context of the subjects267 in a manner that benefits their re-
search. The reason that the research subjects are so attractive is because 
of their social and economic disadvantage. Thus, researchers capitalize 
on this advantage and use it as an entitlement to further exploit the 
vulnerable, using fair opportunity as a guise. However, when applying 
the Human Development Approach to the HIV/AIDS drug trials it is 
clear that the Justice Principle is not entitlement to research, rather it 
imposes specific requirements on researchers or their sponsoring agen-
cies.268 
Applying this Approach to the above-mentioned HIV drug study, 
it is clear that the researchers should never have contacted the States 
to enroll economically disadvantaged minority children in foster care to 
participate in the studies because at the time of the study it was not 
clear that the population was affected by the disease. More specifically, 
it was not clear that any of the children who participated in the studies 
even suffered from HIV/AIDS. Thus, researchers had a duty not to use 
foster children. 
This duty arises from two relationships. First, the researchers were 
often contracting with states that had prevented economically disad-
vantaged children from accessing health care. Because researchers were 
contracting with States that had chosen to limit economically disadvan-
taged children’s access to medical care through under-funding of Med-
icaid, the researchers had a duty to alleviate some of the underlying 
problems faced by economically disadvantaged children, such as lack of 
access to medical treatment. Second, the researchers were citizens affili-
ated with institutions that denied access to care to economically disad-
vantaged minority children. If researchers decided to use economically 
disadvantaged minority children as subjects they had a duty to provide 
a benefit to the vulnerable population from which the subjects originate 
that alleviated some of the populations’ underlying problems, such lack 
of access to health care. 
To measure whether the benefit will alleviate some of the popu-
lations’ underlying problems, I suggest that researchers be required to 
 
266. London, supra note 17, at 26 (“[T]he minimalist view frames the funda-
mental problem of justice in international research in terms of two salient 
variables: the needs and vulnerabilities of the host population, and the ca-
pacity of research to benefit and to burden.”). 
267. Id. at 28. 
268. Id. at 34−35. 
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use the VEIA tool. The VEIA is based in part on Health Equity Impact 
Assessment tools.269 
B. Measuring Justice: Vulnerability and Equity Impact Assessment Tool 
In 1970, the United States became the first country to require im-
pact assessments to attempt to predict the impact of policies on envir-
onmental health.270 Since 1999, many countries, such as Germany, 
Switzerland, the Netherlands, Australia, New Zealand, Canada, and the 
United States, have adopted this tool for use in the health policy field 
to avoid or minimize negative impacts on health.271 Impact assessment 
tools put the burden on those completing the tool to show that their 
actions will not negatively impact the health of the population. 
The Health Impact Assessment (HIA) is “a combination of proce-
dures, methods and tools by which a policy, programme or project may 
be judged as to its potential effects on the health of a population, and 
the distribution of those effects within the population.”272 There are two 
main functions of the HIA: 1) to support policy making when choosing 
between options; and 2) to predict the future consequences of imple-
menting different policy options.273 There are six key stages in using a 
HIA: “screening, scoping, data collection, impact appraisal, reporting/ 
recommendations, and monitoring/evaluation.”274 By using the HIA, 
policymakers can adopt the most beneficial policy for the population’s 
health. Attaining equity in health can be one of the priorities in com-
pleting a HIA. However, equity is not the main focus of the HIA.275 
Although the HIA can determine if the policy will have different im-
pacts on different social groups, the process does not provide informa-
tion concerning whether these differential impacts are a result of unfair 
and biased policies.276 
Consequently, the Health Equity Impact Assessment (HEIA) tool 
was created to ensure that assessments about a policy’s impact would 
 
269. Haber, supra note 18. 
270. National Environmental Policy Act of 1969, 42 U.S.C. § 4321 (2012). 
271. Eur. Observatory on Health Sys. & Policies, The Effectiveness 
of Health Impact Assessment: Scope and Limitations of Support-
ing Decision-Making in Europe 4–5, 17 (Mathias Wismar et. al. eds., 2007). 
272. Id. at 3. (citation omitted). 
273. Id. 
274. Susan L. Povall et al., Health Equity Impact Assessment, 29 Health Pro-
motion Int’l 621, 622 (2013). 
275. Id. at 629. 
276. Id. at 622. This study found that even when equity was a central theme of 
the HIA, the impact analysis did not go beyond identifying vulnerable popu-
lations and the differential effects of the policy on these populations. Id. at 
629. 
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include an evaluation of fairness and equity as well as root causes of 
inequities.277 The HEIA identifies “deeply rooted disparities in income, 
wealth, knowledge, social status and connections” as “[f]undamental 
causes” of health inequity.278 The World Health Organization’s Com-
mission on Social Determinants of Health has recommended the use of 
the HEIA in all global, national, and local policy making.279 New Zea-
land, Australia, Canada, the United Kingdom, the United States, and 
other countries currently use the HEIA.280 There are five steps involved 
in completing a HEIA: 
1. Screening 
Determine if the initiative requires a HEIA. If the initiative has 
the potential to impact the health of vulnerable or disadvantaged 
groups, HEIA is applicable. It is desirable that all initiatives be 
screened.  
2. Scoping 
Identify affected populations or groups and predict key impacts 
(positive or negative) on those groups. Consider a wide range of 
vulnerable or disadvantaged groups to avoid overlooking unex-
pected or unintended consequences of an initiative. 
3. Impact Assessment 
Use available data/evidence to prospectively assess the impacts 
on vulnerable or disadvantaged groups in relation to the broader 
target population. It is both useful and important to consider a 
broader range of evidence including consultation findings and grey 
literature (including project or program reports, informal practice 
guidelines, recommended or promising practices). These sources 
of evidence should be weighed based on their strength and qua-
lity. 
Where there is very limited data/evidence available, note the lack 
of evidence in the assessment or, where possible, implement other 
strategies to gather evidence. Strategies could include conducting 
surveys, focus groups, or consultation with experts or members of 
the affected groups where time permits. 
4. Mitigation Strategy 
Develop evidence-based recommendations to minimize or elimi-
nate negative impacts and maximize positive impacts on vulner-
able or disadvantaged groups. These recommendations comprise 
 
277. Id. at 629. 
278. Id. at 631−32. 
279. Id. at 631. 
280. Ontario Ministry of Health and Long-term Care, Health Equity 
Impact Assessment (HEIA) Workbook 8 n.1 (2012) [hereinafter HEIA 
Workbook]. 
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your mitigation strategy. Uptake of these recommendations in the 
roll out of the initiative will help to ensure that the initiative 
contributes to equity and does not perpetuate or widen existing 
health disparities. Where possible, recommendations should be 
informed by diverse members of the affected communities. 
5. Monitoring and Evaluation 
Determine how the rollout of the initiative will be monitored to 
determine its impacts on vulnerable or disadvantaged groups in 
comparison to other subpopulations or the broader target popu-
lation. The resulting data will enhance the overall evidence base 
for equity-based interventions and can be fed back into the plan-
ning, policy or program development process.281 
Once these steps have been completed, the organization must de-
cide whether or not to implement the policy. 
A Racial Equity Impact Assessment (REIA) tool has also been 
created to identify the impacts of policies on racial and ethnic groups.282 
Governments in Iowa, Connecticut, Seattle, and the United Kingdom 
have adopted the REIA.283 Although the primary focus of the HEIA 
and REIA are to reduce health inequities, I believe that with some 
modification these tools can be used to create a VEIA to determine 
whether economically disadvantaged minority children should partici-
pate in medical research studies. 
Specifically, the VEIA should be used to assess whether a proposed 
medical research study will provide a benefit to economically disadvan-
taged minority children that will alleviate some of the underlying pro-
blems that prevent them from accessing health care. While in this Ar-
ticle, I focus on how the VEIA can be used to protect economically 
disadvantaged minority children, I believe that the VEIA can be used 
to protect all vulnerable populations.284 
 
281. Id. at 14−15. The HEIA Workbook lists “Dissemination” as a fifth step, 
which “involves sharing results and recommendations for addressing equity. 
Dissemination is a cyclical process, interacting with step four (monitoring).” 
Id. at 15. Here, the screening process, where it is decided whether the HEIA 
applies, is treated as step one. 
282. Terry Keleher, Race Forward, An Introduction to Racial Equity Assessment 
Tools: Governing for Racial Equality 29 (Mar. 2014) (presentation on file 
with author). 
283. Id. 
284. The VEIA can also be used to measure whether researchers are complying 
with informed consent. Ruqaiijah A. Yearby, Involuntary Consent: Condi-
tioning Access to Health Care on Participation in Clinical Trials, 44 J.L. 
Med. & Ethics 445−61 (2016); Yearby, supra note 15. 
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1. The VEIA 
First, the researcher must screen the research proposal to identify 
the purpose of the research, what the research seeks to accomplish, and 
whether the research will impact the health and well-being of eco-
nomically disadvantaged minority children. Additionally, the researcher 
must discuss whether the research is a priority for economically disad-
vantaged minority children. This review coincides with the current re-
quirement of showing that the research will add to generalizable sci-
entific knowledge.285 
In order, to answer this question, the researcher must engage eco-
nomically disadvantaged minority children or someone who represents 
their interests, such as child advocates from non-governmental agencies 
like Marian Wright Edelman, the President and Founder of the 
Children’s Defense Fund.286 This screening dovetails with procedures 
used by researchers when they conduct international research to ensure 
that the research is culturally competent.287 Once this introspective 
review, or screening, has occurred and is noted in the research proposal, 
then the researcher must complete the scoping, impact assessment, and 
mitigation strategy steps. 
To complete the scoping step, the researcher must answer the fo-
llowing questions: 
1. What populations are most affected by the condition being 
studied? 
2. If economically disadvantaged minority children are most affec-
ted by the condition, are there other less vulnerable populations 
that can be used for the research? 
3. Will the research alleviate some of the populations’ underlying 
problems? 
4. Will the population from which the subjects originate gain acc-
ess to the treatment after the study is concluded? 
If economically disadvantaged minority children are most affected 
by the condition, then the researcher must assess whether the impacts 
on this population will be negative or positive. To complete the impact 
assessment step, a researcher must use all available data, such as em-
pirical research studies. If there is limited data available, then the re-
searcher should collect data by “conducting surveys, focus groups, or 
 
285. The OHRP Guidebook concerning medical research adds minorities to the 
list of vulnerable populations. OHRP, Institutional Review Board 
Guidebook (1993) (on file with the author). 
286. Children’s Defense Fund, Marian Wright Edelman, ChildrensDefense 
.Org (2017), http://www.childrensdefense.org/about/leadership/marian-
wright-edelman/ [http://perma.cc/7QTP-E6LE]. 
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consultation with experts or members of the affected groups.”288 The 
evidence should be used to answer the following questions: 
1. Disparities: 
a. Are there race, class, and/or age disparities in the number 
of people who suffer the condition or survive from the con-
dition? 
b. Which racial/ethnic groups are currently most advantaged 
and most disadvantaged by the issues this research seeks to 
address? 
c. Which socioeconomic groups are currently most advant-
aged and most disadvantaged by the issues this research 
seeks to address? 
d. Which age groups are currently most advantaged and most 
disadvantaged by the issues this research seeks to address? 
e. How are the advantaged and disadvantaged groups affected 
differently? 
f. What quantitative and qualitative evidence of inequality 
exists? 
g. What evidence is missing or needed? 
h. Will the research exacerbate these disparities?289 
2. Burdens: 
a. What are the barriers to accessing health care for econo-
mically disadvantaged minority children who are potential 
research subjects? 
b. Will participation in medical research studies increase these 
barriers? 
c. Will participation in medical research studies alleviate 
these barriers? 
d. What are the root causes of the barriers to accessing health 
care, such as structural and institutional racial biases? 
e. Will the research address these root causes? 
3. Adverse Impacts: 
a. What potential adverse impacts or unintended consequen-
ces could result from participation in this research beyond 
the burdens? 
b. Will the impacts or unintended consequences further bur-
den economically disadvantaged minority children? 
c. How could adverse impacts be prevented or minimized? 
4.  Equitable Impacts: 
a. What are positive impacts on the populations underlying 
problems, such as increased access to health? 
 
288. HEIA Workbook, supra note 280, at 14–15. 
289. See Keleher, supra note 282, at 30 (providing sample questions to assist in 
assessing the impact of proposed actions on various racial groups). 
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b. Which racial/ethnic groups could benefit? 
c. Which socioeconomic groups could benefit? 
d. Which age groups could benefit? 
e. Are there further ways to alleviate some of the populations’ 
underlying problems?290 
Using the answers from these questions, the researcher must pro-
vide an evidence-based determination of whether economically disad-
vantaged minority children should be used as research subjects because 
the research will alleviate some of the populations’ underlying problems, 
such as access to health care. 
If the researcher decides to use economically disadvantaged min-
ority children as research subjects even though there is a possibility of 
increasing barriers to health care, the researcher must develop a miti-
gation strategy that will alleviate another underlying problem of eco-
nomically disadvantaged minority children such as access to essential 
goods such as food, education, and housing. If there is a mitigation 
strategy, the researcher must monitor the actual strategy and show that 
the strategy has alleviated another underlying problem. 
2. Applying the VEIA 
If researchers are required to apply the VEIA, many research stu-
dies that exploited economically minority children in violation of the 
Justice Principle would never have been funded. 
For example, if the researchers discussed in Section II.B., who used 
African American and Latino foster children to test HIV/AIDS drugs, 
had been required to complete a VEIA, it would have shown the re-
search violated the Justice Principle. 
First, the researchers would have been required to screen the re-
search to identify the purpose of the research, what the research sought 
to accomplish, and whether the research had the potential to affect 
economically disadvantaged minority children.291 
Clearly, the screening would have shown that the medical research 
study had the potential to impact economically disadvantaged minority 
children if they were used as subjects, and it was unclear why healthy 
children had to be used to test HIV/AIDS drugs. Furthermore, there 
was no evidence that this research was a priority to healthy econo-
mically disadvantaged minority children in foster care. If the resear-
chers were able to show that it was a health priority, the research would 
still be prohibited under the scoping step. There was no evidence that 
at the time of the research economically African American and Latino 
children were the group most affected by HIV/AIDS. Therefore, other 
children should have been used. Moreover, the impact assessment of the 
disparities, the burdens, the adverse impacts, and the equitable impacts 
 
290. Id.  
291. See supra Section III.B.1. 
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would have shown that economically disadvantaged minority children 
were negatively impacted with little to no benefit. Specifically, econo-
mically disadvantaged minority children were not the group most affec-
ted by HIV/AIDS (disparities) and the children had barriers to access-
ing health care because they used Medicaid (burdens). The research did 
not address these barriers. In fact, the research increased these barriers 
by making healthy children sick, who had limited access to health care 
(adverse impacts) and did not provide any positive impacts in terms of 
treatment or increasing access to health care (equitable impacts). Thus, 
the children should not have participated in the medical research stu-
dies. 
This is just one example of how using the VEIA to measure the 
redefined Justice Principle will protect economically disadvantaged 
minority children from being exploited. However, the incorporation of 
the Human Development Approach in the Justice Principle and imple-
mentation of the VEIA will not put an end to exploitation without 
changing the current regulatory structure governing medical research 
studies involving children. 
C. A New Regulatory Structure 
In the past OHRP and individual IRBs have been responsible for 
preventing economically disadvantaged minority children from being 
exploited in medical research studies.292 The examples discussed in 
Section II.B. suggest that neither OHRP nor individual IRBs have been 
successful in accomplishing this task. Thus, I suggest the creation of a 
U.S. Human Research Protection Review Board for Children using the 
authority granted by the Common Rule to review medical research 
studies otherwise unapprovable.293 
The Board for Children would be in charge of determining whether 
domestic medical research studies involving children were ethical based 
upon the redefined Justice Principle.294 Before a medical research study 
is conducted, the Board of Children would be required to review the 
research proposal, including the VEIA, to evaluate whether the research 
exploits economically disadvantaged minority children for medical re-
search studies in violation of the redefined Justice Principle. 
To accomplish this task for research governed by the Common 
Rule, the Board for Children needs to have adequate community par-
ticipation and specific requirements for the approval of research. The 
Board for Children must include at least two members of each group 
identified as a vulnerable population in the Common Rule. The Board 
for Children must also consist of at least two physicians that conduct 
 
292. 45 C.F.R. § 46.103(b)(1) (2015); OHRP Memorandum, supra note 81.  
293. 45 C.F.R. § 46.407 (2015). 
294. In addition, the Board can review issues regarding Autonomy and Bene-
ficence.  
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research. However, these physicians cannot be from institutions that 
deny children access to health care or have been cited for violations by 
the OHRP. Finally, the Board for Children should include three bio-
ethicists, two child advocacy members, and two government employees. 
The Board must review the VEIA for all medical research studies 
using children governed by the Common Rule to ensure the studies 
comply with the redefined Justice Principle. This review must occur 
before the researcher submits the proposal for funding. The Board 
would be responsible for reviewing the VEIA for each research proposal 
to make sure that the study was not exploiting economically disadvan-
taged minority children for medical research studies.295 If the VEIA 
shows that there is no exploitation and that the study was necessary 
and safe, then the Board should approve the study and post the VEIA 
on clinicaltrials.gov. 
The creation of the Board is just the beginning of the structural 
changes that need to be made to the regulation of medical research 
studies using children. Additionally, new penalties need to be imposed 
if a researcher and/or institution violates the Justice Principle. Curr-
ently, OHRP just issues letters and suspends researchers from federally 
funded research. Violations of the Justice Principle should also result 
in fines, loss of federal funding, and denial of drug approval. Researchers 
that violate the requirements should also face criminal fines.296 Further-
more, victims of research conducted in violation of the Justice Prin-
ciples should be granted a private right of action against the institution 
and the researcher. 
Conclusion 
Professor Patricia King, one of the drafters of the Belmont Report, 
noted, “[d]espite common recognition that ‘the Tuskegee Study is Am-
erica’s metaphor for racism in medical research,’ there has been inade-
quate attention paid to race, either in the sense of negative and diff-
erential treatment or in terms of pervasive scientific racism, in the con-
struction of bioethics in the United States.”297 Specifically, neither re-
searchers nor those who regulate medical research studies take into acc-
ount structural and institutional racial biases that prevent vulnerable 
 
295. The Board would also be responsible for ensuring that the researchers are 
complying with the other requirement of Justice, which is that members of 
the vulnerable population participating in the study will directly benefit from 
the study. 
296. See, e.g., Richardson, supra note 86, at 127 (discussing the potential deter-
rent effect of criminal punishment on researchers).  
297. Patricia A. King, Reflections on Race and Bioethics in the United States, 14 
Health Matrix 149, 150 (2004) (quoting Susan M. Reverby, Introduction 
to Tuskegee’s Truths, supra note 14, at 3). 
Case Western Reserve Law Review·Volume 67·Issue 4·2017 
Exploitation in Medial Research 
1226 
populations, such as economically disadvantaged minority children, 
from accessing health care, making them vulnerable to exploitation in 
medical research studies that promise access to health care. Thus, 
economically disadvantaged minority children continue to be exploited 
in medical research studies that do not provide a benefit to the popu-
lation from which they originated. 
As Carol Levine notes, “[t]here [has been] no resolution of the con-
flict between American society’s failure to provide basic healthcare and 
HIV/AIDS prevention programs to poor communities of color—a 
matter of social justice—and the potential coerciveness of using research 
participation as an entry into the health care system.”298 Hence, the 
time has come to put an end to this exploitation by enforcing the Jus-
tice Principle to prevent the use of all children, but especially econo-
mically disadvantaged minority children, in medical research studies for 
which they will not receive a benefit. This will only happen if the Justice 
Principle stands for more than inclusion. The Justice Principle must be 
a measurable standard that ensures fairness, equity, and the right of 
children to reach their full health potential without interference. Other-
wise, children will continue to be sacrificed for the benefit of an un-
worthy society. 
 
298. Levine, supra note 1, at 121. 
